U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-QSB
(Mark One)
|X| Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the quarterly period ended March 31, 2001
--------------
[ ] Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the transition period from __________ to
___________.
Commission file number 0-27282
ATLANTIC TECHNOLOGY VENTURES, INC.
----------------------------------
(Exact name of small business issuer as specified in its charter)
Delaware 36-3898269
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
350 Fifth Avenue, Suite 5507, New York, New York 10118
------------------------------------------------------
(Address of principal executive offices)
(212) 267-2503
(Issuer's telephone number)
150 Broadway, Suite 1110, New York, New York 10038
(Former name, former address and former fiscal year, if changed
since last report)
Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes X No _____
-------
Number of shares of common stock outstanding as of May 1, 2001: 6,531,447
Transitional Small Business Disclosure Format (check one): Yes No X
------- -----
INDEX
Page
----
PART I-- FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheets
as of March 31, 2001 (unaudited) and December 31, 2000 3
Consolidated Statements of Operations (unaudited)
for the three months ended March 31, 2001 and 2000,
and the period from July 13, 1993 (inception) to March 31, 2001 4
Consolidated Statements of Cash Flows (unaudited)
for the three months ended March 31, 2001 and 2000,
and the period from July 13, 1993 (inception) to
March 31, 2001 5
Notes to Consolidated Financial Statements (unaudited) 6
Item 2. Management's Discussion and Analysis
of Financial Condition and Results of Operations 10
PART II-- OTHER INFORMATION
Item 1. Legal Matters 14
Item 2. Changes in Securities 14
Item 5. Other Information 15
Item 6. Exhibits and Reports on Form 8-K 21
SIGNATURES
EXHIBIT INDEX
2
PART I -- OTHER INFORMATION
Item 1. Financial Statements
ATLANTIC TECHNOLOGY VENTURES, INC. AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Balance Sheets
March 31, December 31,
Assets 2001 2000
--------------- ------------
(Unaudited)
Current assets:
Cash and cash equivalents $ 2,581,497 2,663,583
Accounts receivable -- 192,997
Prepaid expenses 29,320 22,599
-------------- ------------
Total current assets 2,610,817 2,879,179
Property and equipment, net 259,256 227,088
Investment in affiliate 63,623 67,344
Other assets 22,838 2,901
-------------- ------------
Total assets $ 2,956,534 3,176,512
============== ============
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses $ 779,246 785,838
Deferred revenue -- 1,294,615
-------------- ------------
Total current liabilities $ 779,246 2,080,453
-------------- ------------
Redeemable Series B convertible preferred stock.
Authorized 1,647,312 shares; 0 and 206,898 shares issued and
outstanding at March 31, 2001 and December 31, 2000 respectively. -- 600,000
Stockholders' equity:
Preferred stock, $.001 par value. Authorized 10,000,000
shares; 1,375,000 shares designated as Series A
convertible preferred stock -- --
Series A convertible preferred stock, $.001 par value.
Authorized 1,375,000 shares; 351,588 and 359,711 shares issued and
outstanding at March 31, 2001 and December 31, 2000, respectively
(liquidation preference aggregating $4,570,644 and $4,676,243 at March
31, 2001
and December 31, 2000, respectively) 351 360
Convertible preferred stock warrants, 112,896
issued and outstanding at March 31, 2001 and
December 31, 2000 520,263 520,263
Common stock, $.001 par value. Authorized 50,000,000
shares; 6,458,424 and 6,122,135 shares issued and outstanding
at March 31, 2001 and December 31, 2000, respectively 6,458 6,122
Common stock subscribed. 182 shares at March 31, 2001
and December, 31, 2000 -- --
Additional paid-in capital 24,957,317 24,796,190
Deficit accumulated during development stage (23,306,559) (24,826,334)
-------------- ------------
2,177,830 496,601
Less common stock subscriptions receivable (218) (218)
Less treasury stock, at cost (324) (324)
-------------- ------------
Total stockholders' equity 2,177,288 496,059
-------------- ------------
Total liabilities and stockholders' equity $ 2,956,534 3,176,512
============== ============
See accompanying notes to consolidated financial statements.
3
ATLANTIC TECHNOLOGY VENTURES, INC. AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Statements of Operations
(Unaudited)
Cumulative
period from
July 13, 1993
(inception) to
Three months ended March 31, March 31,
2001 2000 2001
---- ---- ----
Revenues:
Development revenue $ 2,461,922 912,481 8,713,720
License revenue -- -- 2,500,000
Grant revenue 250,000 13,009 616,659
-------------- ------------ -------------
Total revenues 2,711,922 925,490 11,830,379
-------------- ------------ -------------
Costs and expenses:
Cost of development revenue 2,082,568 729,985 7,084,006
Research and development 306,767 127,439 9,829,677
Acquired in-process research and
development -- -- 2,653,382
General and administrative 681,948 495,678 16,567,174
Compensation expense relating to
stock warrants (general and administrative) 11,971 990,820 1,032,836
License fees -- -- 173,500
-------------- ------------ -------------
Total operating expenses 2,963,254 2,343,922 37,220,575
-------------- ------------ -------------
Operating loss (251,332) (1,418,432) (25,390,196)
Other (income) expense:
Interest and other income (20,018) (40,190) (1,271,154)
Interest expense -- -- 625,575
Equity in (earnings) loss of affiliate 3,721 -- 82,995
Gain on sale of Optex assets (2,809,451) -- (2,809,451)
Distribution to Optex minority shareholders 767,514 -- 767,514
-------------- ------------ -------------
Total other (income) expense (1,938,234) (40,190) (2,484,521)
-------------- ------------ -------------
Net income (loss) $ 1,686,902 (1,378,242) (22,905,675)
============== ============ =============
Imputed convertible preferred stock
dividend 600,000 -- 5,931,555
Dividend paid upon repurchase of Series B 167,127 -- 400,884
Preferred stock dividend issued in
preferred shares 64,144 659,319 1,347,207
-------------- ------------ -------------
Net income (loss) applicable to common shares $ 855,631 (2,037,561) (30,585,321)
============== ============ =============
Net income (loss) per share applicable to common shares:
Basic $ 0.13 (0.41)
============== ============
Diluted $ 0.13 (0.41)
============== ============
Weighted average shares of common
stock outstanding:
Basic 6,384,613 4,968,921
============== ============
Diluted 8,237,212 4,968,921
============== ============
See accompanying notes to consolidated financial statements.
4
ATLANTIC TECHNOLOGY VENTURES, INC. AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Statements of Cash Flows
(Unaudited)
Cumulative
period from
July 13, 1993
(inception) to
Three months ended March 31, March 31,
------------------------------
2001 2000 2001
-------------- ------------- -------------
Cash flows from operating activities:
Net income (loss) $ 1,686,902 (1,378,242) (22,905,675)
Adjustments to reconcile net income (loss) to
net cash used in operating activities:
Acquired in-process research and development -- -- 1,800,000
Expense relating to issuance of warrants -- -- 298,202
Expense relating to the issuance of options -- -- 81,952
Expense related to Channel merger -- -- 657,900
Change in equity of affiliate 3,721 -- 82,995
Compensation expense relating to
stock options and warrants 11,971 990,820 1,240,881
Discount on notes payable - bridge financing -- -- 300,000
Depreciation 26,943 15,757 533,448
Gain on sale of Optex assets (2,809,451) -- (2,809,451)
Loss on disposal of furniture and equipment -- -- 73,387
Changes in assets and liabilities:
Decrease in accounts receivable 192,997 17,927 --
Increase in prepaid expenses (6,721) (20,185) (29,320)
Decrease in deferred revenue (1,294,615) -- --
Increase (decrease) in accrued expenses (169,592) (46,815) 616,246
Increase in accrued interest -- -- 172,305
Increase in other assets (19,937) (2,901) (22,838)
-------------- ------------- -------------
Net cash provided by (used in)
operating activities (2,377,782) (423,639) (19,909,968)
-------------- ------------- -------------
Cash flows from investing activities:
Purchase of furniture and equipment (86,660) (6,116) (899,741)
Investment in affiliate -- (250,000) (146,618)
Proceeds from sale of Optex assets 3,000,000 -- 3,000,000
Proceeds from sale of furniture and equipment -- -- 6,100
-------------- ------------- -------------
Net cash provided by (used in)
investing activities 2,913,340 (256,116) 1,959,741
-------------- ------------- -------------
Cash flows from financing activities:
Proceeds from exercise of warrants -- -- 5,500
Proceeds from exercise of stock options -- 321,039 397,098
Proceeds from issuance of demand notes payable -- -- 2,395,000
Repayment of demand notes payable -- -- (125,000)
Proceeds from the issuance of notes payable -
bridge financing -- -- 1,200,000
Proceeds from issuance of warrants -- -- 300,000
Repayment of notes payable - bridge financing -- -- (1,500,000)
Repurchase of common stock -- -- (324)
Preferred stock dividend paid (577) -- (895)
Proceeds from the issuance of common stock -- -- 7,547,548
Proceeds from issuance of convertible preferred stock -- -- 11,441,672
Repurchase of convertible preferred stock (617,067) -- (1,128,875)
-------------- ------------- -------------
Net cash provided by (used in)
financing activities (617,644) 321,039 20,531,724
-------------- ------------- -------------
Net increase (decrease) in cash and
cash equivalents (82,086) (358,716) 2,581,497
Cash and cash equivalents at beginning of period 2,663,583 3,473,321 --
-------------- ------------- -------------
Cash and cash equivalents at end of period $ 2,581,497 3,114,605 2,581,497
============== ============= =============
Supplemental disclosure of non-cash financing
activities:
Issuance of common stock in exchange for
common stock subscriptions $ -- -- 7,027
Conversion of demand notes payable and the related
accrued interest to common stock -- -- 2,442,304
Cashless exercise of preferred warrants -- -- 49,880
Conversion of preferred to common stock 336 289 2,762
Preferred stock dividend issued in shares 64,144 659,324 1,190,024
============== ============= =============
- ---------------
* See accompanying notes to consolidated financial statements.
5
ATLANTIC TECHNOLOGY VENTURES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
March 31, 2001
(1) BASIS OF PRESENTATION
The accompanying consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States
of America for interim financial information. Accordingly, the financial
statements do not include all information and footnotes required by Generally
Accepted Accounting Principles for complete financial statements. In the opinion
of management, the accompanying financial statements reflect all adjustments,
consisting of only normal recurring adjustments, considered necessary for fair
presentation. Interim operating results are not necessarily indicative of
results that may be expected for the year ending December 31, 2001 or for any
subsequent period. These consolidated financial statements should be read in
conjunction with Atlantic Technology Ventures, Inc., and Subsidiaries'
("Atlantic") Annual Report on Form 10-KSB as of and for the year ended December
31, 2000.
(2) LIQUIDITY
Atlantic anticipates that their current liquid resources will be
sufficient to finance their currently anticipated needs for operating and
capital expenditures for at least the next twelve months. In addition, Atlantic
will attempt to generate additional capital through a combination of
collaborative agreements, strategic alliances and equity and debt financing.
However, Atlantic can give no assurance that they will be able to obtain
additional capital through these sources or upon terms acceptable to them.
On March 16, 2001, Atlantic entered into a common stock purchase
agreement with Fusion Capital Fund II, LLC pursuant to which Fusion Capital
agreed to purchase up to $6.0 million of our common stock which will commence
upon effective registration and certain other conditions. A material contingency
that may affect Atlantic's operating plans and ability to raise funds is its
stock price. If its stock price remains at current levels, Atlantic will be
limited in the amount of funds it will be able to draw as defined by the Fusion
Capital agreement. As the Fusion Capital agreement is currently structured,
Atlantic does not have a guarantee that it will be able to draw any funds. See
note 11 below and see liquidity discussion within Management's Discussion and
Analysis of Financial Condition and Results of Operations.
(3) COMPUTATION OF NET INCOME (LOSS) PER COMMON SHARE
Basic net income (loss) per common share is calculated by dividing net
income (loss) applicable to common shares by the weighted average number of
common shares outstanding for the period. Diluted net income (loss) per common
share is calculated by dividing net income (loss) applicable to common shares
plus the impact of the assumed preferred stock conversions totaling $231,271, by
the weighted average common shares outstanding for the period plus 1,888,599
common stock equivalents from assumed conversions of the Series A and Series B
preferred stock if dilutive. The common stock equivalents from stock options,
stock warrants, and stock subscriptions have not been included in the diluted
calculations as their effect is anti-dilutive.
(4) RECENTLY ISSUED ACCOUNTING STANDARDS
On January 1, 2001, Atlantic adopted the provisions of Statement of
Financial Accounting Standards (SFAS) No. 138, "Accounting for Certain
Derivative Instruments and Certain Hedging Activities - an amendment of SFAS No.
133" and SFAS No. 133, "Accounting for Certain Derivative Instruments and
Certain Hedging Activities". SFAS No. 138 amends the accounting and reporting
standards of SFAS No. 133 for certain derivative instruments and certain hedging
activities. SFAS No. 133 requires a company to recognize all derivative
instruments as assets and liabilities in its balance sheet and measure them at
fair value. The adoption of these statements did not have a material impact on
Atlantic's consolidated financial position, results of operations or cash flows,
as Atlantic is currently not party to any derivative instruments.
6
(5) INCOME TAXES
Atlantic generated book income solely in the quarter ended March 31,
2001 as a result of the sale of Optex assets to Bausch & Lomb as described
further in note 10. However, Atlantic does not expect to generated book income
for the year ended December 31, 2001; therefore, no income taxes have been
reflected for the three months ended March 31, 2001.
(6) PREFERRED STOCK DIVIDEND
On January 16, 2001, Atlantic's board of directors declared a
payment-in-kind dividend of 0.065 of a share of Series A convertible preferred
stock ("Series A Preferred") for each share of Series A Preferred held as of the
record date of February 7, 2001. The estimated fair value of this dividend of
$64,144 was included in Atlantic's calculation of net income (loss) per common
share for the three months ended March 31, 2001. The equivalent dividend for the
three months ended March 31, 2000 had an estimated fair value of $659,319 and is
recorded in the same manner.
(7) ISSUANCE OF STOCK WARRANTS
As more fully described in Note 9 to Atlantic's Annual Report on Form
10-KSB as of and for the year ended December 31, 2000, on January 4, 2000,
Atlantic entered into a Financial Advisory and Consulting Agreement with Joseph
Stevens & Company, Inc. pursuant to which Atlantic issued to Joseph Stevens &
Company, Inc. three warrants to purchase an aggregate of 450,000 shares of its
common stock. Atlantic recorded compensation expense relating to these stock
warrants in the amount of $990,820 for the three month period ended March 31,
2000. No such compensation is required subsequent to December 31, 2000.
On March 8, 2001, Atlantic entered into an agreement with The Investor
Relations Group, Inc. (IRG) under which IRG will provide Atlantic investor
relations services pursuant to which Atlantic issued to Dian Griesel warrants to
purchase 120,000 shares of its common stock at an exercise price of $0.875 per
share. These warrants will vest in 5,000 share monthly increments over a 24
month period. In addition, should Atlantic's stock price reach $2.50, Atlantic
will grant Dian Griesel an additional 50,000 warrants. Should Atlantic's stock
price reach $5.00, Atlantic will grant Dian Griesel a further 50,000 warrants.
As a result, Atlantic recorded compensation expense relating to these stock
warrants of $11,971 pursuant to EITF Issue No. 96-18 for the three month period
ended March 31, 2001 and will remeasure the compensation expense at the end of
each reporting period until the final measurement date is reached in 24 months.
Compensation for these warrants represents general and administrative
expense.
(8) REDEEMABLE SERIES B PREFERRED SHARES
On September 28, 2000, pursuant to a Convertible Preferred Stock and
Warrants Purchase Agreement (the Purchase Agreement) Atlantic issued to BH
Capital Investments, L.P. and Excalibur Limited Partnership (together, the
Investors) for a purchase price of $2,000,000, 689,656 shares of Atlantic's
Series B convertible preferred stock (Series B Preferred) and warrants to
purchase 134,000 shares of Atlantic's common stock. Half of the shares of the
Series B Preferred (344,828 shares) and warrants to purchase half of the shares
of common stock (67,000 shares) were held in escrow, along with half of the
purchase price.
On December 4, 2000, Atlantic and the Investors entered into a stock
repurchase agreement (the Stock Repurchase Agreement) pursuant to which Atlantic
repurchased from the investors a portion of the outstanding shares.
Pursuant to Atlantic's renegotiations with the Investors, Atlantic was
required, among other things, to redeem on March 28, 2002, all outstanding
shares of Series B Preferred for (A) 125% of the original issue price per share
or (B) the market price of the shares of common stock into which they are
convertible, whichever is greater (the Redemption Price). Atlantic would have
been able to at any time redeem all outstanding shares of Series B Preferred at
the Redemption Price. As a result of the renegotiations discussed in this
paragraph, the Series B Preferred was considered redeemable and the remaining
outstanding shares at December 31, 2000 were classified
7
outside of permanent equity in the accompanying consolidated balance sheet. At
December 31, 2000, Atlantic had 206,898 shares outstanding at a carrying amount
of $2.90 per share.
Holders of shares of Atlantic's outstanding Series B Preferred could
convert each share into shares of common stock without paying Atlantic any cash.
The conversion price per share of the Series B Preferred was also amended by the
second amendment to the Purchase Agreement. The conversion price per share of
Series B Preferred on any given day is the lower of (1) $1.00 or (2) 90% of the
average of the two lowest closing bid prices on the principal market of the
common stock out of the fifteen trading days immediately prior to conversion.
The change in conversion price upon the renegotiations on January 9, 2001
resulted in a difference between the conversion price of the Series B Preferred
and the market price of the common stock on the effective date of the
renegotiation. This amount, estimated at $600,000, was recorded as an imputed
preferred stock dividend within equity and is deducted from net income (loss) to
arrive at net income (loss) applicable to common shares during the first quarter
of 2001.
On January 19, 2001, 41,380 shares of Series B Preferred were converted
by the Investors into 236,422 shares of Atlantic's common stock. On March 9,
2001, Atlantic and the Investors entered into Stock Repurchase Agreement No. 2,
pursuant to which Atlantic repurchased from the Investors, for an aggregate
purchase price of $617,067, all 165,518 shares of Atlantic's Series B Preferred
held by the Investors on March 9, 2001. The carrying amount of the 165,518
shares is equal to $480,000; therefore the amount in excess of the carrying
amount, which equals $167,127, was recorded as a dividend upon repurchase of
Series B Preferred shares and is deducted from net income (loss) to arrive at
net income (loss) applicable to common shares.
(9) DEVELOPMENT REVENUE
In accordance with an amended license and development agreement, which
was subsequently terminated as described below in note 10, Bausch & Lomb
Surgical reimbursed Atlantic's subsidiary, Optex Ophthalmologics, Inc.
("Optex"), for costs Optex incurred in developing its Catarex(TM) technology,
plus a profit component. For the three months ended March 31, 2001, this
agreement provided $2,461,922 of development revenue, and related cost of
development revenue of $2,082,568. For the three months ended March 31, 2000,
this agreement provided $912,481 of development revenue, and related cost of
development revenue of $729,985. The agreement was terminated in March 2001 (see
note 10 below).
(10) SALE OF OPTEX ASSETS
Pursuant to an asset purchase agreement dated January 31, 2001, among
Bausch & Lomb, a Bausch & Lomb affiliate, Atlantic, and Optex, on March 2, 2001,
Optex sold to Bausch & Lomb substantially all its assets, including all those
related to the Catarex technology. The purchase price was $3 million paid at
closing (approximately $564,000 of which was distributed to Optex's minority
shareholders). In addition, Optex is entitled to receive additional
consideration, namely $1 million, once Bausch & Lomb receives regulatory
approval to market the Catarex device in Japan, royalties on net sales on the
terms stated in the original development agreement dated May 14, 1998, between
Bausch & Lomb and Optex, as amended, and minimum royalties of $90,000, $350,000,
and $750,000 for the first, second, and third years, respectively, starting on
first commercial use of the Catarex device or January 1, 2004, whichever is
earlier. Optex also has the option to repurchase the acquired assets from Bausch
& Lomb if it ceases developing the Catarex technology.
Upon the sale of Optex assets, Bausch & Lomb's development agreement
with Optex was terminated and Optex has no further involvement with Bausch &
Lomb. As a result of this transaction, Atlantic recorded a gain on the sale of
Optex assets of $2,809,451. The purchase price of $3,000,000 is nonrefundable
and upon the closing of the asset purchase agreement in March 2001, Optex has no
further obligation to Bausch & Lomb or with regard to the assets sold. Pursuant
to Atlantic's agreement with the minority shareholders of Optex, Optex made a
profit distribution in March 2001 of $767,514 representing the minority
shareholders' percentage of the cumulative profit from the Bausch & Lomb
development and asset purchase agreements up to and including proceeds from the
sale of Optex' assets. (This figure includes the $564,000 referred to above.)
8
(11) PRIVATE PLACEMENT OF COMMON SHARES
On March 16, 2001, Atlantic entered into a common stock purchase
agreement with Fusion Capital Fund II, LLC pursuant to which Fusion Capital
agreed to purchase up to $6.0 million of our common stock over a 30-month
period, subject to a 6-month extension or earlier termination at our discretion.
The receipt of funds under this agreement will commence upon effective
registration, which Atlantic expects in June 2001, and certain other conditions
being satisfied. The selling price of the shares will be equal to the lesser of
(1) $20.00 or (2) a price based upon the future market price of the common
stock, without any fixed discount to the market price. A material contingency
that may affect Atlantic's operating plans and ability to raise funds is its
stock price. If its stock price remains at current levels, Atlantic will be
limited in the amount of funds it will be able to draw as defined by the Fusion
Capital agreement. As the Fusion Capital agreement is currently structured,
Atlantic does not have a guarantee that it will be able to draw any funds.
Atlantic paid a finder's fee of $120,000 in relation to this agreement in April
2001 which is included in general and administrative expense for the three month
period ended March 31, 2001. Atlantic amended its agreement with Fusion on March
16, 2001, to allow Atlantic to draw funds pursuant to the agreement regardless
of its listing status on the Nasdaq SmallCap Market.
(12) SUBSEQUENT EVENTS
An asset purchase agreement dated April 23, 2001, among Atlantic,
Atlantic's majority-owned subsidiary Gemini Technologies, Inc., the Cleveland
Clinic Foundation (CCF) and CCF's affiliate IFN, Inc. was signed in which Gemini
will sell, upon meeting certain closing conditions, to IFN substantially all its
assets, including all those related to the 2-5A antisense enhancing technology.
The transaction is expected to close during the second quarter of 2001.
9
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
You should read the following discussion of our results of operations
and financial condition in conjunction with our Annual Report on Form 10-KSB for
the year ended December 31, 2000.
RESULTS OF OPERATIONS
THREE MONTH PERIOD ENDED MARCH 31, 2001 VS. 2000
In accordance with a license and development agreement, as amended,
Bausch & Lomb Surgical has reimbursed our subsidiary, Optex Ophthalmologics,
Inc. ("Optex"), for costs Optex incurred in developing its Catarex technology,
plus a profit component. For the three months ended March 31, 2001, this
agreement provided $2,461,922 of development revenue, and related cost of
development revenue of $2,082,568. For the three months ended March 31, 2000,
this agreement provided $912,481 of development revenue, and related cost of
development revenue of $729,985. The primary reason for the substantial increase
in revenues over last year was the recognition of a project completion bonus of
$1,067,345 paid out and recognized at the completion of the project in February
2001. With the termination of the above agreement at the conclusion of the sale
of substantially all of Optex's assets in March 2001, as described further
below, we will no longer have the revenues or profits associated with that
agreement available to us.
For the quarter ended March 31, 2001, research and development expense
was $306,767 as compared to $127,439 in the first quarter of 2000. This increase
is due to increased expenditures on certain development projects including CT-3
as we have been assessing potential markets and developing test plans for a
Phase II study. See the Research and Development section for further details.
For the quarter ended March 31, 2001, general and administrative
expense was $681,948 as compared to $495,678 in the first quarter of 2000. This
increase is largely due to an increase in payroll costs over last year of
approximately $72,000 and a finders fee of $120,000 incurred in conjunction with
a common stock purchase agreement entered into during the first quarter 2001
with Fusion Capital Fund II, LLC pursuant to which Fusion Capital agreed to
purchase up to $6.0 million of our common stock over a 30-month period, subject
to a 6-month extension or earlier termination at our discretion. The receipt of
funds under this agreement will commence upon effective registration and certain
other conditions which are targeted for June 2001. A material contingency that
may affect our operating plans and ability to raise funds is our stock price. If
our stock price remains at current levels, we will be limited in the amount of
funds we will be able to draw as defined by the Fusion Capital agreement. As the
Fusion Capital agreement is currently structured, we do not have a guarantee
that we will be able to draw any funds. See Liquidity and Capital Resources for
further details on this agreement.
For the quarter ended March 31, 2001, we had compensation expense
relating to stock warrants of $11,971 associated with warrants issued to Dian
Griesel during March 2001 as partial compensation for investor relations
services. Additional expense associated with these warrants will continue to be
incurred over the 2 year term of the agreement. For the quarter ended March 31,
2000, we had $990,820 of expense associated with warrants issued to Joseph
Stevens & Company as partial compensation for investment banking services which
was recorded in full as of December 31, 2000.
For the first quarter of 2001, interest and other income was $20,018,
compared to $40,190 in the first quarter of 2000. The decrease in interest
income is primarily due to the decline in our cash reserves.
Net income applicable to common shares for the quarter ended March 31,
2001, was $855,631 as compared to a net loss applicable to common shares of
$2,037,561 for the quarter ended March 31, 2000. This increase in net income is
primarily attributable to a gain on the sale of the assets of our subsidiary,
Optex recognized during the first quarter of 2001 in the amount of $2,809,451,
partially offset by a distribution to the minority shareholders of Optex of
$767,514. (see further discussion of this sale below). In the quarter ended
March 31, 2000, we recorded compensation expense of $990,820 relating to stock
warrants issued to Joseph Stevens & Co. which did not exist during the current
year. Net income (loss) applicable to common shares also included a beneficial
conversion on our Series B preferred stock in the amount of $600,000 and a
dividend paid upon the repurchase of the outstanding Series B preferred stock
recorded during the first quarter of 2001. We also issued preferred stock
dividends on our Series A preferred stock for which the estimated fair value of
$64,144 and $659,319 was included in the net income
10
(loss) applicable to common shares for the first quarter of 2001 and 2000,
respectively. The decrease in the estimated fair value of these dividends as
compared to the prior year is primarily a reflection of a decline in our stock
price and a reduction of the number of preferred shares issued. Going forward,
with the termination of our cost plus a profit component agreement with Bausch &
Lomb, described below, we will no longer have the revenue or profits associated
with that agreement available to us. For the year ended December 31, 2000, we
received $5,169,288 in development revenue from Bausch & Lomb.
LIQUIDITY AND CAPITAL RESOURCES
From inception to March 31, 2001, we incurred an accumulated deficit of
$23,306,559, and we expect to continue to incur additional losses through the
year ending December 31, 2001 and for the foreseeable future. The loss has been
incurred through primarily research and development activities related to our
various technologies under our control.
Pursuant to an asset purchase agreement dated January 31, 2001, among
Bausch & Lomb, a Bausch & Lomb affiliate, Atlantic, and Optex, on March 2, 2001,
Optex sold to Bausch & Lomb substantially all its assets, including all those
related to the Catarex technology. The purchase price was $3 million paid at
closing (approximately $564,000 of which was distributed to the minority
shareholders). In addition, Optex is entitled to receive additional
consideration, namely $1 million once Bausch & Lomb receives regulatory approval
to market the Catarex device in Japan, royalties on net sales on the terms
stated in the original development agreement dated May 14, 1998, between Bausch
& Lomb and Optex, as amended, and minimum royalties of $90,000, $350,000, and
$750,000 for the first, second, and third years, respectively, starting on first
commercial use of the Catarex device or January 1, 2004, whichever is earlier.
Optex also has the option to repurchase the acquired assets from Bausch & Lomb
if it ceases developing the Catarex technology. Upon the sale of Optex assets,
Bausch & Lomb's development agreement with Optex was terminated. As a result of
this transaction, we recorded a gain on the sale of Optex assets of $2,809,451.
Pursuant to our agreement with the minority shareholders of Optex, we made a
profit distribution of $767,514 representing the minority shareholders'
percentage of the cumulative profit from the Bausch & Lomb cost plus 25 percent
agreement up to and including proceeds from the sale of Optex' assets.
On September 28, 2000, pursuant to a convertible preferred stock and
warrants purchase agreement (the purchase agreement), we issued to BH Capital
Investments, L.P. and Excalibur Limited Partnership (together, the Investors)
for a purchase price of $2,000,000, 689,656 shares of our Series B convertible
preferred stock (the Series B preferred stock) and warrants to purchase 134,000
shares of our common stock. Half of the shares of Series B preferred stock
(344,828 shares) and warrants to purchase half of the shares of common stock
(67,000 shares) were held in escrow, along with half of the purchase price.
On December 4, 2000, Atlantic and the Investors entered into a stock
repurchase agreement (the stock repurchase agreement) pursuant to which we
repurchased from the Investors for $500,000 137,930 shares of Series B preferred
stock, and agreed to the release from escrow to the Investors of the $1,000,000
purchase price of the 344,828 shares of Series B preferred stock held in escrow.
We also allowed the Investors to keep all of the warrants issued under the
purchase agreement and issued to the Investors warrants to purchase a further
20,000 shares of our common stock at the same exercise price. On January 19,
2001, 41,380 shares of Series B preferred stock were converted by the Investors
into 236,422 shares of our common stock. On March 9, 2001, Atlantic and the
Investors entered into a second stock repurchase agreement (stock repurchase
agreement no. 2). Pursuant to stock repurchase agreement no. 2, we repurchased
from the Investors, for an aggregate purchase price of $617,067, all 165,518
shares of our Series B preferred stock held by the Investors. The repurchase
price represented 125% of the purchase price originally paid by the investors
for the repurchased shares, as well as an amount equal to the annual dividend on
the Series B preferred stock at a rate per share of 8% of the original purchase
price. The repurchased shares constitute all remaining outstanding shares of
Series B preferred stock; we have cancelled those shares.
On March 16, 2001, we entered into a common stock purchase agreement
with Fusion Capital Fund II, LLC pursuant to which Fusion Capital agreed to
purchase up to $6.0 million of our common stock over a 30-month period, subject
to a 6-month extension or earlier termination at our discretion. The receipt of
funds under this agreement will commence upon effective registration and certain
other conditions which are targeted for June 2001. The selling price of the
shares will be equal to the lesser of (1) $20.00 or (2) a price based upon the
future market price of the common stock, without any fixed discount to the
market price. A material contingency that may affect our operating plans and
ability to raise funds is our stock price. If our stock price remains at current
levels, we will
11
be limited in the amount of funds we will be able to draw as defined by the
Fusion Capital agreement. As the Fusion Capital agreement is currently
structured, we do not have a guarantee that we will be able to draw any funds. A
$120,000 finders fee relating to this transaction was paid to Gardner Resources,
Ltd. We have amended our agreement with Fusion Capital to allow Atlantic to draw
funds pursuant to the agreement regardless of its listing status on the Nasdaq
SmallCap Market.
Our available working capital and capital requirements will depend upon
numerous factors, including progress of our research and development programs;
our progress in and the cost of ongoing and planned preclinical and clinical
testing; the timing and cost of obtaining regulatory approvals; the cost of
filing, prosecuting, defending, and enforcing patent claims and other
intellectual property rights; competing technological and market developments;
changes in our existing collaborative and licensing relationships; the resources
that we devote to developing manufacturing and commercializing capabilities;
technological advances; status of competitors; our ability to establish
collaborative arrangements with other organizations; and our need to purchase
additional capital equipment.
At March 31, 2001, we had $2,581,497 in cash and cash equivalents and
working capital of $1,831,571. We anticipate that our current resources will be
sufficient to finance our currently anticipated needs for operating and capital
expenditures for at least the next twelve months. In addition, we will attempt
to generate additional capital through a combination of collaborative
agreements, strategic alliances, and equity and debt financing. However, we can
give no assurance that we will be able to obtain additional capital through
these sources or upon terms acceptable to us.
We have the following short term and long term liquidity needs. Our
cash utilized for operations for the next year is expected to be approximately
$200,000 per month. Currently, these expected operating expenses include
approximately $70,000 per month for research and pre-clinical development
expenses and approximately $130,000 for general and administrative expenses.
Based on our cash position of $2,581,497 at March 31, 2001, we will either have
to raise additional funds within the next twelve months to fund our current
spending requirements or we will have to reduce or eliminate the planned levels
of development activities. Since we do not have significant fixed cash
commitments, we have the option of significantly cutting or delaying our
development activities as may be necessary. To meet these needs in the short
term, we expect to begin drawing funds in the amount of $200,000 per month from
Fusion Capital starting in June 2001, once we have an effective registration. If
our agreement with Fusion Capital is not finalized, or if we are unable to draw
funds from Fusion Capital, we will seek alternative funding sources. These
funding sources include seeking other equity financing and working toward
licensing CT-3 later in 2001.
A material contingency that may affect our operating plans and ability
to raise funds is our stock price. If our stock price remains at current levels,
we will be limited in the amount of funds we will be able to draw as defined to
the Fusion Capital agreement. As the Fusion Capital agreement is currently
structured, we do not have a guarantee that we will be able to draw any funds.
We are at risk of being delisted from the Nasdaq SmallCap Market. As of
March 20, 2001, we had the thirtieth consecutive business day that the minimum
bid price of our common stock was less than $1.00. This constitutes a failure on
our part to meet Nasdaq's continued inclusion requirement for minimum bid price.
On March 22, 2001, Nasdaq notified us of this failure, and we have a period of
90 calendar days from that notice to comply with the continued inclusion
standard for minimum bid price. We can do so by meeting the standard for a
minimum of 10 consecutive business days during the 90 day compliance period.
In addition, the consolidated financial statements included with our
2000 Annual Report on Form 10-KSB for the year ended December 31, 2000, show
that on December 31, 2000, our net tangible assets were less than $2 million.
Consequently, we received a deficiency notice from Nasdaq notifying us that we
had ten days to submit a plan to achieve and sustain long-term compliance with
all applicable listing criteria. On May 2, 2001, we submitted our plan to
Nasdaq. If Nasdaq is not satisfied with the plan that we submitted, we will then
receive a staff determination from Nasdaq. Upon receipt of the staff
determination, we will have seven days to appeal the staff determination and
request a hearing before Nasdaq's Listing Qualifications Panel, and such a
request will generally stay the delisting pending a determination by the panel
(called a "panel decision"). Failure to request a hearing within seven calendar
days will result in automatic delisting. If our securities were delisted, it
could materially and adversely affect our ability to raise additional funding.
12
RESEARCH AND DEVELOPMENT ACTIVITIES
For a description of Atlantic's research and development activities,
see Item 5 of Part II entitled "Other Information."
13
PART II -- OTHER INFORMATION
Item 1. Legal Matters
Claim for Arbitration Brought by Cleveland Clinic Foundation
Atlantic's subsidiary, Gemini, has an exclusive worldwide sublicense
from the Cleveland Clinic Foundation to a U.S. patent and related patent
applications, as well as corresponding foreign applications, relating to 2-5A
chimeric antisense technology and its use for selective degradation of targeted
RNA. On May 8, 2000, the Cleveland Clinic Foundation filed a claim for
arbitration before the American Arbitration Association to terminate this
sublicense, claiming that Gemini has breached the sublicense by failing to
fulfill its obligations under the sublicense. Pursuant to an asset purchase
agreement dated April 23, 2001, among the Cleveland Clinic Foundation and its
new affiliate IFN, Inc., Atlantic and Gemini, Gemini has agreed to sell to IFN
substantially all its assets, including all those related to the 2-5A antisense
enhancing technology in the second quarter of 2001. Upon the closing of this
transaction, which we expect will occur in May 2001, the Cleveland Clinic will
withdraw its outstanding arbitration demand against Gemini and Atlantic, with
prejudice, and each party will be obligated to pay its own costs and attorney's
fees related thereto. For additional information, please see Item 5 under the
subheading "Gemini and the 2-5A Antisense Technology."
Item 2. Changes in Securities
Recent Sales of Unregistered Securities
Issuance to BH Capital Investments, L.P. and Excalibur Limited Partnership
On September 28, 2000, pursuant to a convertible preferred stock and
warrants purchase agreement (the "purchase agreement"), we issued to BH Capital
Investments, L.P. and Excalibur Limited Partnership (together, the "Investors")
for a purchase price of $2,000,000, 689,656 shares of our Series B convertible
preferred stock (the "Series B preferred stock") and warrants to purchase
134,000 shares of our common stock. Half of the shares of Series B preferred
stock (344,828 shares) and warrants to purchase half of the shares of common
stock (67,000 shares) were held in escrow, along with half of the purchase
price.
On December 4, 2000, Atlantic and the Investors entered into a stock
repurchase agreement (the "stock repurchase agreement") pursuant to which we
repurchased from the Investors for $500,000 137,930 shares of Series B preferred
stock, and agreed to the release from escrow to the Investors of the $1,000,000
purchase price of the 344,828 shares of Series B preferred stock held in escrow.
We also allowed the Investors to keep all of the warrants issued under the
purchase agreement and issued to the Investors warrants to purchase a further
20,000 shares of our common stock at the same exercise price.
The issuance of the shares of Series B preferred stock and warrants did
not involve any public offering and therefore was exempt from registration
pursuant to Section 4(2) of the Securities Act of 1933.
The warrants are exercisable at the fixed exercise price or 110% of the
market price 180 days after the date of issuance, whichever is lower. Pursuant
to a second amendment to the purchase agreement, executed on January 9, 2001,
the fixed exercise price of the warrants was lowered from $3.19, the fixed
exercise price upon their issuance, to $1.00, the market price of our common
stock at the time of the renegotiations. Each warrant may be exercised any time
during the five years from the date of granting. The warrants may not be
exercised if doing so would result in our issuing a number of shares of common
stock in excess of the limit imposed by the rules of the Nasdaq SmallCap Market.
Holders of shares of our outstanding Series B preferred stock can
convert each share into shares of common stock without paying Atlantic any cash.
The conversion price per share of the Series B preferred stock was also amended
by the second amendment to the purchase agreement. The conversion price per
share of Series B preferred stock on any given day is the lower of (1) $1.00 or
(2) 90% of the average of the two lowest closing bid prices on the principal
market of the common stock out of the fifteen trading days immediately prior to
conversion.
14
On March 9, 2001, Atlantic and the Investors entered into stock
repurchase agreement no. 2. Pursuant to stock repurchase agreement no. 2, we
repurchased from the Investors, for an aggregate purchase price of $617,067, all
165,518 shares of our Series B preferred stock held by the Investors. The
repurchase price represented 125% of the purchase price originally paid by the
investors for the repurchased shares, as well as an amount equal to the annual
dividend on the Series B preferred stock at a rate per share of 8% of the
original purchase price. The repurchased shares constitute all remaining
outstanding shares of Series B preferred stock; we have cancelled those shares.
Issuance to The Investor Relations Group, Inc.
On March 8, 2001, Atlantic entered into an agreement with The Investor
Relations Group, Inc. (IRG) under which IRG will provide Atlantic investor
relations services pursuant to which Atlantic issued to Dian Griesel warrants to
purchase 120,000 shares of its common stock. These warrants will vest in 5,000
share monthly increments over a 24 month period. In addition, should Atlantic's
stock price reach $2.50, Atlantic will grant Dian Griesel an additional 50,000
warrants. Should Atlantic's stock price reach $5.00, Atlantic will grant Dian
Griesel a further 50,000 warrants. As a result, Atlantic recorded compensation
expense relating to these stock warrants of $11,971 for the three month period
ended March 31, 2001 and will remeasure the compensation expense at the end of
each reporting period until the final measurement date is reached in 24 months.
The term of the warrants is five years and the exercise price of the
warrants is $0.875.
The issuance of the warrants did not involve any public offering and
therefore was exempt from registration pursuant to Section 4(2) of the
Securities Act of 1933.
Item 5. Other Information
Research and Development Activities
Optex and the Catarex Technology
Our majority-owned (81.2%) subsidiary, Optex Ophthalmologics, Inc., is
entitled to royalties and other revenues in connection with commercialization of
the Catarex cataract-removal technology. Bausch & Lomb Incorporated, a
multinational ophthalmics company, is developing this technology to overcome the
limitations and deficiencies of traditional cataract extraction techniques.
Pursuant to an asset purchase agreement dated January 31, 2001, between B&L, a
B&L affiliate, Atlantic, and Optex, on March 2, 2001, Optex sold to B&L
substantially all its assets, including all those related to the Catarex
technology. Management believes that B&L will aggressively pursue
commercialization of the Catarex technology. To that end, B&L has informed us
that it expects to begin human clinical trials of the device in the beginning of
the third quarter of 2001 at a variety of investigations sites, and that it is
working to develop the next generation handpiece and is working to integrate the
Catarex device with B&L's Millenium Surgical platform.
CT-3
We are developing CT-3, a synthetic derivative of the major active
ingredient in marijuana, as the lead compound in the series of patented
compounds. CT-3 has been tested in a Phase I clinical trial and in many
pre-clinical in vitro and in vivo studies to profile its potential activity and
to evaluate its usefulness in treating medical conditions.
Our development plan for CT-3 is focused on developing CT-3 for chronic
pain and inflammation associated with a variety of disease states. This
indication covers a broad range of conditions, including headaches, cancer pain,
arthritis and arthritis pain, low back pain, fibromyalgia, neuropathic pain and
psychogenic pain. We have recently initiated a development plan for CT-3 to test
its efficacy in multiple sclerosis. We propose to test these assumptions by
conducting preliminary studies in animal models predictive of efficacy in
humans. We are also preparing to conduct phase II clinical trials to evaluate
the efficacy of CT-3 in multiple sclerosis associated tremors and spasticity.
15
Our development program for CT-3 as a treatment for pain and
inflammation associated with a variety of disease states in ongoing as well. We
are continuing our efforts by conducting additional pre-clinical tests to study
the analgesic activity of CT-3, particularly with reference to neuropathic pain.
We are planning to initiate shortly a phase I/II clinical trial of safety,
tolerability, and efficacy to determine the upper limits of safe dosing with
CT-3 and to measure the potential for CT-3 to act as a pain reliever in patients
with neuropathic pain.
Market and Competition
Initially, Atlantic will be developing CT-3 for chronic pain and
inflammation associated with a variety of disease states. Some of these
indications include neuropathic pain, arthritis pain, cancer pain, headaches,
low back pain and psychogenic pain. It is estimated that over 130 million people
in the US alone suffer from chronic pain. The market for the treatment of
chronic pain and inflammation is large and highly competitive. The worldwide
market for analgesics/anti-inflammatory agents was over $9 billion in 1999
(Company Reports, analyst reports, and Med Ad News review of brands for 1999,
doesn't include disease-modifying drugs such as Enbrel and Arava). In addition,
in the U.S. alone, the OTC market for internal analgesics is over $2 billion,
including major brands and private label products (primarily ibuprofen,
acetaminophen, and naproxen, Chain Drug Review). There is significant upside
potential if the many prescriptions of generic narcotics and NSAIDS can be
replaced by CT-3. The drug with the highest number of prescriptions in 1999 was
hydrocodone in combination with acetaminophen, with over 58.8 million
prescriptions.
Several multinational pharmaceutical companies currently have many
popular products in this market and many companies have active research programs
to identify and develop more potent and safer anti-inflammatory and analgesic
agents. One notable area of research is in the development of "COX-2 inhibitors"
that are claimed to be safer to the stomach than available NSAIDs. (COX-2
inhibition is not considered a significant contributor to the mechanism of
action of CT-3; in vitro studies have shown very weak COX-2 inhibition.) Two
COX-2 inhibitor compounds have recently received FDA approval and several others
are in various stages of clinical development. We believe that the potential
advantages of CT-3 make it worth developing, and that if we succeed, CT-3 could
become a significant new agent in the treatment of pain and inflammation.
In addition to the analgesic and anti-inflammatory markets, CT-3 has
the potential to be an effective therapeutic for other markets as mentioned
earlier. One such potential market is the neurological market. CT-3 has the
potential to be a safe and effective treatment for the management and symptoms
of MS. With an estimated 3 million MS patients worldwide, spasticity is a major
concern for many patients and physicians. Approximately 90 percent of MS
patients eventually develop spasticity.
Gemini and the 2-5A Antisense Technology
An asset purchase agreement dated April 23, 2001, among Atlantic,
Atlantic's majority-owned subsidiary Gemini Technologies, Inc., the Cleveland
Clinic Foundation, or "CCF," and CCF's affiliate IFN, Inc., was signed, in which
Gemini will sell to IFN substantially all its assets, including all those
related to the 2-5A antisense enhancing technology. The transaction is expected
to close in the second quarter of 2001. The closing is subject to closing
conditions standard for a transaction of this kind.
The Cleveland Clinic Sublicense
In May 1994 Gemini obtained an exclusive worldwide sublicense from CCF
to a U.S. patent and related patent applications, as well as corresponding
foreign applications, relating to 2-5A Chimeric Antisense Technology and its use
for selective degradation of targeted RNA. (That sublicense is referred to as
the "CCF sublicense.") The rights exclusively licensed to Gemini included rights
obtained by CCF through an interinstitutional agreement with the National
Institutes of Health, or "NIH," the co-owner of the patent rights. The term of
the CCF sublicense was until expiration of the underlying patent rights, and
under the CCF sublicense Gemini was required to pay to CCF as royalties 40
percent of income from sales of products and processes incorporating the
licensed technology. Gemini had to satisfy other requirements in order to retain
its license rights under the CCF Sublicense. For one thing, it was required to
take effective steps to achieve practical application of the sublicensed
technology. Failure by CCF to discharge its obligations to the NIH under the
interinstitutional agreement could have resulted in termination of the
interinstitutional agreement and, in turn, our access to the technology.
16
Research and Development Activities Through 1999
Gemini conducted research at its own laboratory facilities and
sponsored research at the NIH and CCF focusing on two main objectives: (1)
advancing basic research into the 2-5A technology, with a view to making 2-5A
cheaper to synthesize and increasing its clinical utility and (2) developing a
potential lead product candidate to demonstrate 2-5A's clinical utility.
Research has to date been conducted primarily in in vitro systems and has
included studies of infectious diseases (respiratory syncytial virus, or "RSV,"
herpes, and human immunodeficiency virus, or "HIV"), certain cancers (chronic
myelogenous leukemia, glioblastoma), conditions modulated by 5-alpha reductase
and dihydrotestosterone receptors (acne and androgenic alopecia), and aspects of
the interferon pathway that are mediated by PKR (a protein kinase enzyme).
Based on these data, Gemini decided initially to focus more of its
efforts on studies of RSV and telomerase, an enzyme believed to be critical for
the growth and survival of some cancers. Data collected to date indicate that
the molecule to be tested had greater in vitro potency than Ribavarin, an
FDA-approved treatment for RSV infections; these data were published in the
Proceedings of the National Academy of Sciences, a peer-review research journal.
This molecule has also been shown to be stable against degradative enzymes and
capable of being absorbed into lung tissue when administered in a droplet
formulation. Gemini concluded that the next step in development would be to
conduct an in vivo proof-of-principle study, preferably in primates. It began
exploring optimal manufacturing processes to produce sufficient quantities
needed in an in vivo study, and anticipated, but could give no assurance, that
such a study would establish proof-of-efficacy in primates. Further in vivo
studies would likely be necessary to firmly establish optimal dosing regimens.
Gemini believed that focusing its antisense program on a lead target
like primate-oriented RSV would allow it to demonstrate the clinical utility of
the 2-5A and enable it to more effectively pursue corporate partnerships to
further develop the technology. If it could complete such a partnership, the
research and development of the technology could have been expanded into some of
the aforementioned and additional areas of potential clinical use.
The lead compound against telomerase demonstrated convincing
proof-of-concept in a limited in vivo (nude mice) model where human glioblastoma
(the most common form of primary brain cancer) cells were transplanted into the
animals. The data were subsequently published in Oncogene, a peer-review journal
dedicated to cancer research. However, the development status of using of 2-5A
against the telomerase target was well behind that of using it against RSV.
Deteriorating Relations with the Cleveland Clinic
In 1999, after a change in management subsequent to a consent
solicitation process conducted by members of our current board of directors, our
new management team led by A. Joseph Rudick began critically assessing our
technology portfolio, including 2-5A, with a view to increasing the
profitability or cost effectiveness of each project without sacrificing quality
or speed of development.
Dr. Rudick met with CCF in September 1999 to discuss the status of the
2-5A development project. At that time, and in a letter sent the following
month, CCF formally informed us that in its view Gemini had not performed its
obligations under the terms of the Cleveland sublicense. In its letter, CCF
demanded that Atlantic and Gemini either (1) take prompt action to cure their
alleged defaults; (2) relinquish control of the technology and return all rights
to CCF, or (3) renegotiate the terms of the sublicense, limiting Gemini's
control of the 2-5A technology and return some of the rights to CCF. In
response, Atlantic informed CCF that Gemini would attempt to cure its alleged
defaults, and as a first step would immediately hold a meeting of Gemini's
Scientific Advisory Board as requested by CCF. In addition, Atlantic continued
to press both CCF and the NIH to comply with the provisions of the Cleveland
sublicense that required both CCF and the NIH to sublicense to Gemini several
method-of-use improvement patents for using 2-5A for the treatment of RSV and
telomerase.
Atlantic then hired Hoyle Consulting, Inc., a Frederick, Maryland-based
regulatory consulting and clinical management consulting firm to independently
assess the all aspects of 2-5A development activities to date and prepare a
project plan for developing 2-5A for the treatment of RSV. A project plan
represents a standard first step in drug development and gives management the
information necessary to determine whether to proceed with a project or
terminate it.
17
After attending a meeting of Gemini's Scientific Advisory Board in
November 1999, Hoyle began preparing the project plan for 2-5A. Hoyle's first
task was to investigate the operational details and costs of making the 2-5A
drug substance in bulk. Hoyle received a quotation of $5,500 per gram to
manufacture the 2-5A drug substance, and on that basis determined that
performing a 28-day repeated dose toxicity study of 2-5A in dogs, one of the
most basic pre-clinical studies required by the FDA for an Investigational New
Drug, or "IND," application, would require approximately 400 grams of the drug
at a cost of $2.2 million. Moreover, since Gemini proposed to develop 2-5A to be
administered in aerosolized route of administration form (by inhalation, not
intranasal), the FDA could require that the dog toxicity studies be conducted by
multiple routes of administration, requiring both inhalation and intravenous
toxicity studies, which would require a greater quantity of the drug. Additional
quantities would be required for rat toxicology studies, pharmacokinetic studies
in both species used for the toxicity studies, formulation research, methods
development, and clinical trial supplies. In short, Hoyle concluded that the
high cost of obtaining the 2-5A drug substance in bulk raised serious concerns
about the continued economic viability of the 2-5A project.
We found Hoyle's concerns to be warranted, and we conveyed them CCF by
letter in January 2000. We further noted that Gemini had spent over $3 million
developing the 2-5A drug, thereby enabling it to be brought through an initial
proof-of-principle primate study, and that we were also concerned that we might
be infringing certain patents, thereby making our investment in 2-5A potentially
more risky and costly. Accordingly, we expressed our desire to explore various
options with CCF with regard to amending the Cleveland sublicense or terminating
it in return for appropriate compensation, given the value Gemini had added.
In a letter dated April 2000, CCF responded to Dr. Rudick's overture by
claiming that CCF considered Gemini's license to be terminated. CCF requested
that Gemini acknowledge that the sublicense was terminated and that Atlantic and
Gemini release CCF from any claims. CCF also threatened to resort to arbitration
to terminate the sublicense.
On May 5, 2000, Dr. Rudick, now Atlantic's CEO and Gemini's President,
and Fred Zotos, Atlantic's newly appointed President flew to CCF's attorney's
offices in Cleveland, Ohio, in an attempt to reach an agreement on returning the
Cleveland sublicense while avoiding the cost of arbitration. The parties could
not, however, agree upon terms.
Cleveland Clinic Files Arbitration Demand
On May 8, 2000, CCF filed a claim for arbitration before the American
Arbitration Association to terminate the Cleveland sublicense, claiming that we
had breached the sublicense by failing to fulfill our obligations. More
specifically, CCF's claims included the following alleged breaches:
(a) Gemini failed to adequately fund and otherwise advance and
pursue development of the 2-5A technology.
(b) Gemini failed to adequately staff the research team assigned
to develop the 2-5A technology.
(c) Gemini failed to provide specific benchmarks, established in
consultation with the Scientific Advisory Board, outlining all
research and development for the 2-5A technology.
(d) Gemini failed to provide adequate annual financial statements
on a regular and timely basis.
(e) Gemini failed to exercise diligence in developing the
technology.
(f) Gemini failed to establish a Cleveland-based business as
opposed to a Cleveland research facility.
In its response, Gemini denied each of these allegations. More
specifically, Gemini's views as to each allegation were, respectively, as
follows:
(a) Gemini had adequately funded and otherwise advanced
development of the 2-5A technology. Since entering into the
Cleveland sublicense in 1994, Gemini had expended
approximately $3,964,829
18
developing the 2-5A technology, of which approximately
$540,000 went to CCF and $414,521 went to the NIH for
sponsored research, $285,330 was spent on patent prosecution
fees, and $130,839 went to CCF employees acting as
consultants. These expenditures do not include any general and
administrative expenses incurred by Atlantic in overseeing
development of the 2-5A technology over the seven-year period
of the sublicense. The remainder of these expenditures were
spent on staffing, equipping, and operating the Gemini lab
facility in Cleveland, Ohio.
(b) Gemini had adequately staffed the research team assigned to
the development of the 2-5A technology. Gemini's research
staff included a Scientific Director, two full-time research
chemists, and a full-time and a part-time research biologist.
In addition, Gemini had scientific consulting agreements with
two CCF employees, an Atlantic employee was President of
Gemini, an Atlantic employee served half-time as Gemini's
Vice-President of Business Development and Licensing, and
Atlantic hired Hoyle Consulting, Inc., to coordinate the 2-5A
clinical development program.
(c) For each of the last three years Gemini had provided specific
benchmarks in the form of a detailed commercial development
plan. These benchmarks were established in consultation with
the Scientific Advisory Board at regular meetings of the
board, and outlined all research and development for the 2-5A
technology.
(d) Gemini's financial statements were consolidated with
Atlantic's, which are publicly available. Moreover, throughout
this period Gemini did not have any earnings to report and did
not owe CCF any royalties.
(e) Any assessment of how diligent Gemini was in developing the
technology must take into account that the antisense
technology in general, and the 2-5A antisense enhancement
technology in particular, are still experimental and involve
development, targeting, and testing of extremely challenging
molecules. One indication of this is that only one antisense
product, Vitravene by Novartis/Isis, has received FDA
approval, in 1998, even though Isis was incorporated in 1989
and the antisense field is now over twenty years old.
(f) Gemini established in Cleveland, Ohio, a 1400-sq.-ft.
laboratory containing a fully equipped biosafety-level-2 cell
culture facility and adjoining office space. This space
supported four full-time and one-part-time research scientists
and the two CCF consultants. And while Gemini acknowledged
that Atlantic employees managed some Gemini-related matters at
its offices in New York, New York, the Cleveland sublicense
did not specifically require that Gemini establish a Cleveland
based business, as opposed to a Cleveland based research
facility.
In light of Gemini's observations regarding CCF's arbitration claims,
Gemini determined that CCF's claims were without merit and intended to
vigorously defend the action instead of forfeiting the Cleveland sublicense
without compensation for the value added by Gemini's contribution to development
of the 2-5A technology.
Gemini's Continued Development of 2-5A Antisense
Despite the initiation of the arbitration, Gemini elected to continue
developing the 2-5A technology rather than risk having any cessation of
development activities be held to be a breach of the Cleveland sublicense.
Accordingly, Gemini continued to seek a Small Business Innovation Research, or
"SBIR," phase II research grant to allow it to conduct pre-clinical efficacy
studies of 2-5A in primates.
On August 14, 2000, Gemini was awarded a $750,000 SBIR phase II grant
by the National Institute for Allergy and Infectious Diseases, or "NIAID," a
unit of the NIH. Gemini intended to use the grant to fund a pre-clinical
efficacy study using aerosolized 2-5A to inhibit RSV in monkeys, as well as the
toxicological and pharmacological studies Gemini would need in order to file an
IND application with the FDA to begin clinical studies in humans. The goals of
the two-year research plan were as follows:
19
o to improve upon the synthesis and purification procedures required
for efficient scale-up production of the lead 2-5A compound;
o to develop methodologies for aerosolized delivery of 2-5A to the
lungs;
o to carry the lead 2-5A compound through definitive pre-clinical
animal efficacy studies;
o to develop methodologies for analyzing 2-5A integrity in nasal
passages, bronchial lavages and serum of treated animals; and
o to perform preliminary toxicology and pharmacokinetic studies on
2-5A in preparation for an IND filing leading to Phase I clinical
trials.
Efforts to Settle the Arbitration
Shortly after filing its demand for arbitration, CCF appointed a new
director of its Innovations unit, which managed the Cleveland sublicense with
Gemini. This, together with Gemini's receipt of the SBIR grant, led Atlantic and
Gemini to approach CCF again with a view to settling the arbitration. Gemini
proposed that it continue to develop 2-5A with the aim at using the
SBIR-grant-funded primate efficacy trial to reduce overall 2-5A dosage costs by
improving both drug delivery through an aerosolized formulation and decreasing
drug costs by refining the chemical process. If successful, in addition to
providing in vivo proof of efficacy, the study would reduce the overall 2-5A
dosage costs to a more acceptable level. This would have made 2-5A a more
attractive licensing opportunity for a corporate partner. In any event, Gemini
realized that it would be next to impossible to sublicense its rights to another
party as long as its rights under the Cleveland sublicense were the subject of
an arbitration. A further obstacle to licensing 2-5A to a corporate partner was
the fact that Gemini did not have a sublicense from CCF and the NIH to the
method of use patent for 2-5A for RSV, as required by the Cleveland sublicense.
Accordingly, through late 2000 and early 2001 the parties made efforts
to arrive at a settlement. To that end, Gemini held a meeting of its Scientific
Advisory Board in November 2000 and invited the representatives of CCF to
participate as observers. Based upon development goals agreed upon at this
meeting, Gemini formulated a revised development plan.
In February 2001, CCF forwarded a formal settlement offer to Gemini
outlining its numerous conditions for settlement based upon continuing the
Cleveland sublicense with Gemini. These settlement demands required that Gemini
dramatically increase expenditures, personnel, and development efforts on the
2-5A project well above their historic levels. These settlement terms did not
attempt to make any such increased investment more attractive to Gemini by
increasing Gemini's share of royalties (CCF would still have received 40% of any
sublicensing income and owned 7.5% of Gemini's stock), and did not provide for
CCF and the NIH to sublicense to Gemini the method of use patents as required by
the Cleveland sublicense. Moreover, Gemini learned, based on estimates quoted,
that 2-5A manufacturing costs had doubled over the previous year to $11,000 per
gram. Finally, Gemini was still concerned about potential patent infringement as
a result of practicing the 2-5A technology. Taken together, these factors led
Gemini to reject CCF's settlement offer and resulted in Gemini's offer to CCF
that it instead purchase Gemini's assets. CCF accepted this offer.
Asset Purchase Agreement and Arbitration Settlement
The purchase price is an amount equal to 20 percent of all amounts that
CCF is entitled pursuant to the Cleveland sublicense, subject to adjustments.
The purchase price will be reduced by 1 percent of the sublicense fees for each
$150,000 expended by IFN to develop the technology, subject to a floor of 5
percent. In addition, upon closing CCF will withdraw its outstanding arbitration
demand against Gemini and Atlantic, with prejudice, and each party will be
obligated to pay its own costs and attorneys' fees related thereto.
We feel that this solution, if consummated, will represent a
satisfactory alternative to two undesirable alternatives, namely (1) termination
of the Cleveland sublicense with no compensation to Gemini and substantial
shutdown costs and (2) continued development of 2-5A at levels that Gemini would
not be able to justify or sustain.
20
TeraComm
TeraComm is developing a fiber optic transmitter that uses a
high-temperature superconductor (HTS) material to switch a laser beam on and off
with a high-speed electronic digital signal. HTS materials have zero electrical
resistance at low temperatures (< 70 K), and also can have very high optical
reflectance in their super conducting state while they can transmit light in
their normal (non-super conducting) state. TeraComm discovered that a small
electric current in an HTS material could switch the material between states,
and do so very quickly--in less than a millionth millionth of a second. Because
the HTS optical switch works best at far infrared wavelengths and these optical
waves are too large to send through an optical fiber, the TeraComm invention
employs an optical wavelength converter to change the waves to the band that is
just right for the fiber.
Thus far, TeraComm has successfully developed methods of producing
effective HTS thin-films with metal electrodes, has successfully demonstrated
control of optical transmission in HTS films using electric current, and has
been awarded patents covering implementation of this technology for fiber optic
telecommunications. TeraComm has not yet achieved the technical milestone that
it needs to achieve for further progress in developing their technology.
TeraComm has informed us that it is seeking to raise additional funding to
continue its development program and achieve this technical milestone.
Due to our need to preserve our cash resources and due to our
uncertainty regarding TeraComm's plans for developing its technology, we
ultimately paid only $1 million of the $5 million cash portion of the purchase
price. As a consequence, we were required to surrender to TeraComm a number of
our shares of TeraComm's preferred stock, which had the effect of reducing to
14.4% our actual ownership interest. However, Atlantic continues to hold one
seat on the Board of Directors and therefore continues to have the ability to
exert influence.
Item 6: Exhibits and Reports on Form 8-K
Exhibits
The following documents are referenced or included in this report.
Exhibit No. Description
- ----------- -----------
3.1(1) Certificate of Incorporation of Atlantic, as amended to date.
3.2(1) Bylaws of Atlantic, as amended to date.
3.3(5) Certificate of Designations of Series A Convertible Preferred
Stock.
3.4(6) Certificate of Increase of Series A Convertible Preferred
Stock.
3.5(9) Certificate of Designations, Preferences and Rights of Series
B Convertible Preferred Stock of Atlantic, filed on September
28, 2000.
3. 6(9) Certificate of Amendment of the Certificate of Designations,
Preferences and Rights of Series B Convertible Preferred Stock
of Atlantic, filed on November 17, 2000.
3.7(10) Certificate of Amendment of the Certificate of Designations,
Preferences and Rights of Series B Convertible Preferred Stock
of Atlantic, filed on January 9, 2001.
3.8(10) Certificate of Amendment of the Certificate of Designations,
Preferences and Rights of Series B Convertible Preferred Stock
of Atlantic, filed on January 19, 2001.
4.2(1) Form of Unit certificate.
4.3(1) Specimen Common Stock certificate.
21
4.4(1) Form of Redeemable Warrant certificate.
4.5(1) Form of Redeemable Warrant Agreement by and between Atlantic
and Continental Stock Transfer & Trust Company.
4.6(1) Form of Underwriter's Warrant certificate.
4.7(1) Form of Underwriter's Warrant Agreement by and between
Atlantic and Joseph Stevens & Company, L.P.
4.8(1) Form of Subscription Agreement by and between Atlantic and the
Selling Stockholders.
4.9(1) Form of Bridge Note.
4.10(1) Form of Bridge Warrant.
4.11(2) Investors' Rights Agreement by and among Atlantic, Dreyfus
Growth and Value Funds, Inc. and Premier Strategic Growth
Fund.
4.12(2) Common Stock Purchase Agreement by and among Atlantic, Dreyfus
Growth and Value Funds, Inc. and Premier Strategic Growth
Fund.
10.2(1) Employment Agreement dated July 7, 1995, between Atlantic and
Jon D. Lindjord.
10.3(1) Employment Agreement dated September 21, 1995, between
Atlantic and Dr. Stephen R. Miller.
10.4(1) Employment Agreement dated September 21, 1995, between
Atlantic and Margaret A. Schalk.
10.5(1) Letter Agreement dated August 31, 1995, between Atlantic and
Dr. H. Lawrence Shaw.
10.6(1) Consulting Agreement dated January 1, 1994, between Atlantic
and John K. A. Prendergast.
10.8(1) Investors' Rights Agreement dated July 1995, between Atlantic,
Dr. Lindsay A. Rosenwald and VentureTek, L.P.
10.9(1) License and Assignment Agreement dated March 25, 1994, between
Optex Ophthalmologics, Inc., certain inventors and NeoMedix
Corporation, as amended.
10.10(1) License Agreement dated May 5, 1994, between Gemini Gene
Therapies, Inc. and the Cleveland Clinic Foundation.
10.11(1)+ License Agreement dated June 16, 1994, between Channel
Therapeutics, Inc., the University of Pennsylvania and certain
inventors, as amended.
10.12(1)+ License Agreement dated March 28, 1994, between Channel
Therapeutics, Inc. and Dr. Sumner Burstein.
10.13(1) Form of Financial Advisory and Consulting Agreement by and
between Atlantic and Joseph Stevens & Company, L.P.
10.14(1) Employment Agreement dated November 3, 1995, between Atlantic
and Shimshon Mizrachi.
10.15(3) Financial Advisory Agreement between Atlantic and Paramount
dated September 4, 1996 (effective date of April 15, 1996).
10.16(3) Financial agreement between Atlantic, Paramount and UI USA
dated June 23, 1996.
22
10.17(3) Consultancy agreement between Atlantic and Dr. Yuichi Iwaki
dated July 31, 1996.
10.18(3) 1995 stock option plan, as amended.
10.19(3) Warrant issued to an employee of Paramount Capital, LLC to
purchase 25,000 shares of Common Stock of Atlantic.
10.20(3) Warrant issued to an employee of Paramount Capital, LLC to
purchase 25,000 shares of Common Stock of Atlantic.
10.21(3) Warrant issued to an employee of Paramount Capital, LLC to
purchase 12,500 shares of Common Stock of Atlantic.
10.22(4) Letter Agreement between Atlantic and Paramount Capital, Inc.
dated February 26,1997.
10.23(4) Agreement and Plan of Reorganization by and among Atlantic,
Channel Therapeutics, Inc. and New Channel, Inc. dated
February 20, 1997.
10.24(4) Warrant issued to John Prendergast to purchase 37,500 shares
of Atlantic's Common Stock.
10.25(4) Warrant issued to Dian Griesel to purchase 24,000 shares of
Atlantic's Common Stock.
10.26(7) Amendment No.1 to Development & License Agreement by and
between Optex and Bausch & Lomb Surgical, Inc. dated September
16, 1999.
10.27(8) Financial Advisory and Consulting Agreement by and between
Atlantic and Joseph Stevens & Company, Inc. dated January 4,
2000.
10.28(8) Warrant No.1 issued to Joseph Stevens & Company, Inc. to
purchase 150,000 shares of Atlantic's Common Stock exercisable
January 4, 2000.
10.29(8) Warrant No.2 issued to Joseph Stevens & Company, Inc. to
purchase 150,000 shares of Atlantic's Common Stock exercisable
January 4, 2001.
10.30(8) Warrant No.3 issued to Joseph Stevens & Company, Inc. to
purchase 150,000 shares of Atlantic's Common Stock exercisable
January 4, 2002.
10.31(9) Preferred Stock Purchase Agreement dated May 12, 2000, between
Atlantic and TeraComm Research, Inc.
10.32(9) Warrant Certificate issued May 12, 2000, by Atlantic to
TeraComm Research, Inc.
10.33(9) Stockholders Agreement dated May 12, 2000, among TeraComm
Research, Inc., the common stockholders of TeraComm, and
Atlantic.
10.34(9) Registration Rights Agreement dated May 12, 2000, between
Atlantic and TeraComm Research, Inc. with respect to shares of
TeraComm preferred stock issued to Atlantic.
10.35(9) Registration Rights Agreement dated May 12, 2000, between
Atlantic and TeraComm Research, Inc. with respect to shares of
Atlantic common stock issued to TeraComm.
10.36(9) Employment Agreement dated as of April 10, 2000, between
Atlantic and A. Joseph Rudick.
10.37(9) Employment Agreement dated as of April 3, 2000, between
Atlantic and Frederic P. Zotos.
23
10.38(9) Employment Agreement dated as of April 10, 2000, between
Atlantic and Nicholas J. Rossettos, as amended.
10.39(9) Employment Agreement dated as of May 15, 2000, between
Atlantic and Walter Glomb.
10.40(9) Employment Agreement dated as of April 18, 2000, between
Atlantic and Kelly Harris.
10.41(10) Amendment dated as of July 18, 2000, to the Preferred Stock
Purchase Agreement dated May 12, 2000, between Atlantic and
TeraComm Research, Inc.
10.42(10) Convertible Preferred Stock and Warrants Purchase Agreement
dated September 28, 2000, among Atlantic, BH Capital
Investments, L.P. and Excalibur Limited Partnership.
10.43(10) Registration Rights Agreement dated September 28, 2000 among
Atlantic, BH Capital Investments, L.P., and Excalibur Limited
Partnership.
10.44(10) Escrow Agreement dated September 28, 2000 among Atlantic, BH
Capital Investments, L.P., and Excalibur Limited Partnership.
10.45(10) Form of Stock Purchase Warrants issued on September 28, 2000
to BH Capital Investments, L.P., exercisable for shares of
common stock of Atlantic.
10.46(10) Form of Stock Purchase Warrants issued on September 28, 2000
to Excalibur Limited Partnership, exercisable for shares of
common stock of Atlantic.
10.47(10) Amendment No. 1, dated October 31, 2000, to Convertible
Preferred Stock and Warrants Purchase Agreement dated
September 28, 2000, among Atlantic, BH Capital Investments,
L.P., and Excalibur Limited Partnership.
10.48(12) Stock Repurchase Agreement, dated December 4, 2000, among
Atlantic, BH Capital Investments, L.P., and Excalibur Limited
Partnership.
10.49(14) Letter Agreement, dated December 28, 2000, among Atlantic and
BH Capital Investments, L.P., and Excalibur Limited
Partnership.
10.50(11) Amendment No. 2, dated January 9, 2001, to Convertible
Preferred Stock and Warrants Purchase Agreement dated
September 28, 2000, among Atlantic, BH Capital Investments,
L.P., and Excalibur Limited Partnership.
10.51(14) Amendment No. 1, dated January 9, 2001, to Registration Rights
Agreement dated September 28, 2000, among Atlantic and BH
Capital Investments, L.P. and Excalibur Limited Partnership.
10.52(11) Amendment No. 3, dated January 19, 2001, to Convertible
Preferred Stock and Warrants Purchase Agreement dated
September 28, 2000, among Atlantic, BH Capital Investments,
L.P., and Excalibur Limited Partnership.
10.53(14) Letter Agreement, dated January 25, 2001, among Atlantic and
BH Capital Investments, L.P., and Excalibur Limited
Partnership.
10.54(13) Stock Repurchase Agreement No. 2, dated March 9, 2001, among
Atlantic, BH Capital Investments, L.P., and Excalibur Limited
Partnership.
10.55* Common Stock Purchase Agreement, dated March 16, 2001, between
Atlantic and Fusion Capital Fund II, LLC.
10.56* Warrant Certificate, issued March 8, 2001 by Atlantic to Dian
Griesel.
24
21.1(1) Subsidiaries of Atlantic.
24.1 Power of Attorney (included in Part III of this Report under
the caption "Signatures").
- ---------------
+ Confidential treatment has been granted as to certain portions of these
exhibits.
* Filed herewith.
(1) Incorporated by reference to exhibits of Atlantic's
Registration Statement on Form SB-2, Registration #33-98478,
as filed with the Securities and Exchange Commission (the
"SEC") on October 24, 1995 and as amended by Amendment No. 1,
Amendment No. 2, Amendment No.3, Amendment No. 4 and Amendment
No. 5, as filed with the Commission on November 9, 1995,
December 5, 1995, December 12, 1995, December 13, 1995 and
December 14, 1995, respectively.
(2) Incorporated by reference to exhibits of Atlantic's Current
Report on Form 8-KSB, as filed with the SEC on August 30,
1996.
(3) Incorporated by reference to exhibits of Atlantic's Form
10-QSB for the period ended September 30, 1996.
(4) Incorporated by reference to exhibits of Atlantic's Form
10-QSB for the period ended March 31, 1996.
(5) Incorporated by reference to exhibits of Atlantic's Current
Report on Form 8-KSB, as filed with the SEC on June 9, 1997.
(6) Incorporated by reference to exhibits of Atlantic's
Registration Statement on Form S-3 (Registration No.
333-34379), as filed with the Commission on August 26, 1997,
and as amended by Amendment No. 1 as filed with the SEC on
August 28, 1997.
(7) Incorporated by reference to exhibits of Atlantic Form 10-QSB
for the period ended September 30, 1999.
(8) Incorporated by reference to exhibits of Atlantic's Form
10-KSB for the period ended December 31, 1999.
(9) Incorporated by reference to exhibits of Atlantic's Form
10-QSB for the period ended June 30, 2000.
(10) Incorporated by reference to exhibits of Atlantic's Form
10-QSB for the period ended September 30, 2000.
(11) Incorporated by reference to exhibits of Atlantic's Form 8-K
filed on January 24, 2001.
(12) Incorporated by reference to exhibits of Atlantic's Form 8-K
filed on December 11, 2000.
(13) Incorporated by reference to exhibits of Atlantic's Form 8-K
filed on March 14, 2001.
(14) Incorporated by reference to exhibits of Atlantic's Form
10-KSB filed on April 17, 2001.
Reports on Form 8-K
On January 24, 2001, Atlantic filed with the SEC a report on Form 8-K
reporting the renegotiation of the terms of the investment for shares of
Atlantic's Series B convertible preferred stock made by BH Capital
25
Investments, L.P. and Excalibur Limited Partnership (the "Investors") in order
to address concerns raised by Atlantic stockholders and the NASDAQ stock market.
On January 30, 2001, Atlantic filed with the SEC a report on Form 8-K
stating that Atlantic and the Investors had further amended certain terms of the
investment.
On February 5, 2001, Atlantic filed with the SEC a report on Form 8-K
stating that on January 31, 2001, Atlantic and Optex Ophthalmologics, Inc.
("Optex"), a majority-owned subsidiary of Atlantic, signed an asset purchase
agreement (the "Optex Agreement") with Bausch & Lomb, Incorporated ("Bausch &
Lomb") and Bausch & Lomb Surgical, Inc., a wholly-owned subsidiary of Bausch &
Lomb, providing for the sale of substantially all of Optex's assets to Bausch &
Lomb.
On March 14, 2001, Atlantic filed with the SEC a report on Form 8-K
stating that, pursuant to stock repurchase agreement no. 2 among Atlantic and
the Investors, Atlantic repurchased from the Investors all shares of Atlantic's
Series B convertible preferred stock held by the Investors.
On March 16, 2001, Atlantic filed with the SEC a report on Form 8-K
reporting the sale on March 2, 2001, by Optex to Bausch & Lomb of substantially
all the assets of Optex, pursuant to the asset purchase agreement dated January
31, 2001, among Bausch & Lomb, a Bausch & Lomb affiliate, Atlantic, and Optex.
26
SIGNATURES
In accordance with the requirements of the Exchange Act, Atlantic
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
ATLANTIC TECHNOLOGY VENTURES, INC.
Date: May 3, 2001 /s/ Frederic P. Zotos
---------------------------
Frederic P. Zotos
President
Date: May 3, 2001 /s/ Nicholas J. Rossettos
---------------------------
Nicholas J. Rossettos
Chief Financial Officer
27
Exhibit 10.55
EXECUTION COPY
COMMON STOCK PURCHASE AGREEMENT
COMMON STOCK PURCHASE AGREEMENT (the "Agreement"), dated as of March
16, 2001 by and between ATLANTIC TECHNOLOGY VENTURES, INC., a Delaware
corporation, (the "Company"), and FUSION CAPITAL FUND II, LLC, an Illinois
limited liability company, (together with its permitted assigns, the "Buyer").
Capitalized terms used herein and not otherwise defined herein are defined in
Section 10 hereof.
WHEREAS:
Subject to the terms and conditions set forth in this Agreement, the
Company wishes to sell to the Buyer, and the Buyer wishes to buy from the
Company, up to Six Million Dollars ($6,000,000) of the Company's common stock,
par value $0.001 per share (the "Common Stock"). The shares of Common Stock to
be purchased hereunder are referred to herein as the "Purchase Shares."
NOW THEREFORE, the Company and the Buyer hereby agree as follows:
1. PURCHASE OF COMMON STOCK.
Subject to the terms and conditions set forth in Sections 6, 7 and 9
below, the Company hereby agrees to sell to the Buyer, and the Buyer hereby
agrees to purchase from the Company, shares of Common Stock as follows:
(a) Commencement of Purchases of Common Stock. The purchase and sale
of Common Stock hereunder shall commence (the "Commencement") within five (5)
Trading Days following the date of satisfaction (or waiver) of the conditions to
the Commencement set forth in Sections 6 and 7 below (or such later date as is
mutually agreed to by the Company and the Buyer), (the date of such
Commencement, the "Commencement Date").
(b) Buyer's Purchase Rights and Obligations. Subject to the provisions
of Sections 1(d) and 1(g), the Buyer: (i) shall purchase shares of Common Stock
during each Monthly Period equal to the Monthly Base Amount at the Purchase
Price in accordance with Section 1(e), and (ii) at any time on or after the
Maturity Date, shall have the right to purchase shares of Common Stock up to the
entire remaining Available Amount at the Purchase Price in accordance with
Section 1(e). Within three (3) Trading Days of receipt of Purchase Shares, the
Buyer shall pay to the Company an amount equal to the Purchase Amount with
respect to such Purchase Shares as full payment for the purchase of the Purchase
Shares so received. The Company shall not issue any fraction of a share of
Common Stock upon any purchase. All shares of Common Stock (including fractions
thereof) issuable upon a purchase under this Agreement shall be aggregated for
purposes of determining whether the purchase would result in the issuance of a
fraction of a share of Common Stock. If, after the aforementioned aggregation,
the issuance would result in the issuance of a fraction of a share of Common
Stock, the Company shall round such fraction of a share of Common Stock up or
down to the nearest whole share. All payments made under this Agreement shall be
made in lawful money of the United States of America by check or wire transfer
of immediately available funds to such account as the Company may from time to
time designate by written notice in accordance with the provisions of this
Agreement. Whenever any amount expressed to
be due by the terms of this Agreement is due on any day which is not a Trading
Day, the same shall instead be due on the next succeeding day which is a Trading
Day.
(c) Company's Mandatory Purchase Rights. If (A) the Closing Sale Price
of the Common Stock on each of the five (5) Trading Days immediately prior to
the first Trading Day of any Monthly Period is at least $5.00 and (B) no Event
of Default has occurred and is continuing, then the Company shall have the
right, so long as no Event of Default has occurred and is continuing and so long
as the Sale Price of the Common Stock remains at least $5.00 during such Monthly
Periods, by delivering written notice (a "Mandatory Purchase Notice") to the
Buyer on or prior to the first Trading Day of such Monthly Period to require
that the Buyer purchase at the applicable Purchase Price such Available Amount
as specified by the Company in the Mandatory Purchase Notice during the next two
Monthly Periods on such Trading Days during such Monthly Periods as the Buyer
shall determine. The Company acknowledges and agrees that the Company's
Mandatory Purchase Rights represent an agreement by the Buyer to extend
financial accommodations to the Company. Accordingly, it shall be a condition to
the exercise of the Company's Mandatory Purchase Rights that no Event of Default
shall have occurred and is continuing, and the Company's delivery of a Mandatory
Purchase Notice shall be deemed a representation to the Buyer that no Event of
Default has occurred and is continuing. The Company may revoke a Mandatory
Purchase Notice, in whole or in part, by delivering written notice thereof to
the Buyer (a "Revocation of Mandatory Purchase Notice"). A Revocation of
Mandatory Purchase Notice shall be effective only as to Purchase Notices which
are in excess of the Monthly Base Amount and which have a Purchase Date later
than three (3) Trading Days after receipt by the Buyer of the Revocation of
Mandatory Purchase Notice. Any Purchase Notices submitted by the Buyer which
have a Purchase Date on or prior to the third (3rd) Trading Day after receipt by
the Buyer of the Revocation of Mandatory Purchase Notice must be honored by the
Company as otherwise provided herein.
(d) Limitations on Purchases.
(i) Intentionally Omitted.
(ii) Limitation on Beneficial Ownership. The Company shall not
effect any purchase under this Agreement and the Buyer shall not have
the right to purchase shares of Common Stock under this Agreement to
the extent that after giving effect to such purchase the Buyer together
with its affiliates would beneficially own in excess of 4.9% of the
outstanding shares of the Common Stock following such purchase. For
purposes hereof, the number of shares of Common Stock beneficially
owned by the Buyer and its affiliates or acquired by the Buyer and its
affiliates, as the case may be, shall include the number of shares of
Common Stock issuable in connection with a Purchase Notice under this
Agreement with respect to which the determination is being made, but
shall exclude the number of shares of Common Stock which would be
issuable upon (1) a purchase of the remaining Available Amount which
has not been submitted for purchase, and (2) exercise or conversion of
the unexercised or unconverted portion of any other securities of the
Company (including, without limitation, any warrants) subject to a
limitation on conversion or exercise analogous to the limitation
contained herein beneficially owned by the Buyer and its affiliates. If
the 4.9% limitation is ever reached the Company shall have the option
to increase such limitation to 9.9% by delivery of written notice to
the Buyer. Thereafter, if the 9.9% limitation is ever reached this
shall not effect or limit the Buyer's obligation to purchase the
Monthly Base Amount or the Company's Mandatory Purchase Rights as
otherwise provided in this Agreement. For purposes of this Section, in
determining the number of outstanding shares of Common Stock the Buyer
may rely on the number of outstanding shares of Common Stock as
reflected in (1) the Company's most recent Form 10-Q or Form 10-K, as
the case may be, (2) a more recent public announcement by the Company
or (3) any other written communication by the Company or its transfer
agent setting forth the number of shares of Common Stock outstanding.
Upon the reasonable written or oral request of the Buyer, the Company
shall promptly confirm orally and in writing to the Buyer the number of
shares of Common Stock then outstanding. In any case, the number of
outstanding shares of Common Stock shall be determined after giving
effect to any purchases under this Agreement by the Buyer since the
date as of which such number of outstanding shares of Common Stock was
reported. Except as otherwise set forth herein, for purposes of this
Section 1(d)(ii), beneficial ownership shall be determined in
accordance with Section 13(d) of the Securities Exchange Act of 1934,
as amended.
(iii) Company's Right to Suspend Purchases. If at any time the
Closing Sale Price of the Common Stock is below the Fixed Purchase
Price for three consecutive Trading Days, the Company shall have three
(3) Trading Days from the last day of such three consecutive Trading
Day period to give written notice (a "Purchase Suspension Notice") to
the Buyer suspending any and all purchases by the Buyer under this
Agreement. The Purchase Suspension Notice shall be effective only for
Purchase Notices which have a Purchase Date later than three (3)
Trading Days after receipt of the Purchase Suspension Notice by the
Buyer. Any Purchase Notices submitted by the Buyer which have a
Purchase Date on or prior to the third (3rd) Trading Day after receipt
by the Buyer of a Purchase Suspension Notice from the Company must be
honored by the Company as otherwise provided herein. Such purchase
suspension shall continue in effect until the earlier of: (A)
revocation in writing by the Company, at its sole discretion; or (B)
such time as the Sale Price of the Common Stock is above the Fixed
Purchase Price. After the delivery to the Buyer of a Purchase
Suspension Notice from the Company, the Buyer shall no longer be
obligated to purchase any Purchase Shares from the Company under
Section 1 of this Agreement.
(e) Mechanics of Purchasing. The purchase of shares of Common Stock
under this Agreement shall be conducted in the following manner:
(i) Buyer's Delivery Requirements. To purchase shares of
Common Stock under this Agreement on any date, the Buyer shall transmit
by facsimile (or otherwise deliver) on or prior to 11:59 p.m., Central
Time on such date, a copy of a fully executed notice of purchase
substantially in the form attached hereto as Exhibit A (the "Purchase
Notice") to the Company.
(ii) Company's Response. Upon receipt by the Company of a copy
of a Purchase Notice, the Company shall as soon as practicable, but in
no event later than one (1) Trading Day after receipt of such Purchase
Notice, send via facsimile (or otherwise deliver), a confirmation of
receipt of such Purchase Notice in the form attached hereto as Exhibit
B (a "Company Confirmation of Purchase Notice") to (1) the Buyer and
(2) along with a copy of the Purchase Notice, the Company's designated
transfer agent (the "Transfer Agent"), which confirmation shall
constitute an irrevocable instruction to the Transfer Agent to process
such Purchase Notice in accordance with the terms herein. Upon receipt
by the Transfer Agent of a copy of the executed Purchase Notice and a
copy of the applicable Company Confirmation of Purchase Notice, the
Transfer Agent shall, on the first (1st) Trading Day following the date
of receipt of the Company Confirmation of Purchase Notice, (A) provided
the Transfer Agent is participating in The Depository Trust Company's
("The DTC") Fast Automated Securities Transfer Program, credit such
aggregate number of shares of Common Stock to which the Buyer shall be
entitled to the Buyer's or its designee's balance account with The DTC
through its Deposit Withdrawal At Custodian ("DWAC") system, or (B) if
the Transfer Agent is not participating in The DTC Fast Automated
Securities Transfer Program and DWAC system, issue and surrender to a
common carrier for overnight delivery to the address as specified in
the Purchase Notice, a certificate, registered in the name of the Buyer
or its designee, for the number of shares of Common Stock to which the
Buyer shall be entitled.
3
(iii) Dispute Resolution. In the case of a dispute as to the
determination of the Purchase Price, the Company shall instruct the
Transfer Agent to issue to the Buyer the number of shares of Common
Stock that is not disputed and shall submit the disputed determinations
or arithmetic calculations to the Buyer via facsimile within one (1)
Trading Day of receipt of the Buyer's Purchase Notice. If the Buyer and
the Company are unable to agree upon the determination of the Purchase
Price within one (1) Trading Day of such disputed determination being
submitted to the Buyer, then the Company shall within one (1) Trading
Day submit via facsimile the disputed determination of the Purchase
Price to an independent, reputable investment bank selected by the
Company and approved by the Buyer. The Company shall cause the
investment bank to perform the determinations and notify the Company
and the Buyer of the results no later than the fifth (5th) day after
the date it receives the disputed determination of Purchase Price. Such
investment bank's determination shall be binding upon all parties
absent manifest error.
(iv) Record Holder. The person or persons entitled to receive
the shares of Common Stock issuable upon a purchase under this
Agreement shall be treated for all purposes as the record holder or
holders of such shares of Common Stock on the Purchase Date.
(v) Company's Failure to Timely Deliver Shares. If within five
(5) Trading Days after the Company's receipt of a copy of the Purchase
Notice properly submitted in accordance with the term and conditions of
this Agreement (subject to extension in accordance with Section
1(e)(iii) for a good faith dispute in accordance with the terms of
Section 1(e)(iii)) (the "Share Delivery Period"), the Transfer Agent
fails to issue Purchase Shares via credit to the Buyer's account with
The DTC for the number of Purchase Shares to which the Buyer is
entitled upon the Buyer's submission of the applicable Purchase Notice
(a "Purchase Failure"), in addition to all other available remedies
which the Buyer may pursue under applicable laws and this Agreement
(including indemnification obligations of the Company set forth in
Section 8 hereof), the Company shall pay in cash, on demand, additional
damages to the Buyer for each day after such fifth (5th) Trading Day
that the issuance of such Purchase Shares is not timely effected, in an
amount equal to 1.5% of the product of (I) the number of Purchase
Shares not issued to the Buyer on a timely basis pursuant to Section
1(e)(ii) and to which the Buyer is entitled and (II) the Closing Sale
Price of the Common Stock on the Purchase Date.
(vi) Book Entry. Notwithstanding anything to the contrary set
forth herein, upon purchase of any portion of the Available Amount in
accordance with the terms hereof, the Buyer shall not be required to
physically surrender this Agreement to the Company. The Buyer and the
Company shall each maintain records showing the remaining Available
Amount at any give time and the dates and Purchase Amounts for each
purchase or shall use such other method, reasonably satisfactory to the
Buyer and the Company, so as not to require physical surrender of this
Agreement upon each purchase. The Buyer and any assignee, by acceptance
of this Agreement, acknowledge and agree that, by reason of the
provisions of this paragraph, following purchase of any portion of the
Available Amount, the remaining Available Amount under this Agreement
shall then be less than the aggregate Available Amount set forth on the
face hereof.
(f) Taxes. The Company shall pay any and all taxes that may be payable
with respect to the issuance and delivery of any shares of Common Stock to the
Buyer made under of this Agreement.
(g) Compliance with Principal Market Rules. The Company shall not
effect any purchase under this Agreement and the Buyer shall not have the right
to purchase shares of Common Stock under this Agreement to the extent that after
giving effect to such purchase the "Exchange Cap" shall be deemed to be reached.
The "Exchange Cap" shall be deemed to have been reached if, at any time prior to
the
4
shareholders of the Company approving the transaction contemplated by this
Agreement, upon submission of a Purchase Notice under this Agreement, the
Purchase Shares issuable pursuant to such Purchase Notice would, together with
all Purchase Shares previously issued under this Agreement, exceed 1,291,684
shares of Common Stock (19.9% of the 6,458,424 outstanding shares of Common
Stock as of the date of this Agreement). The Company may, but shall be under no
obligation to, request its shareholders to approve the transaction contemplated
by this Agreement. The Company shall not be required or permitted to issue any
shares of Common Stock under this Agreement if such issuance would breach the
Company's obligations under the rules or regulations of the Principal Market.
2. BUYER'S REPRESENTATIONS AND WARRANTIES.
The Buyer represents and warrants to the Company that:
(a) Investment Purpose. The Buyer is entering into this Agreement and
acquiring the Commitment Shares (as defined in Section 7(b) hereof) (this
Agreement and the Commitment Shares are collectively referred to herein as the
"Securities"), for its own account for investment only and not with a view
towards, or for resale in connection with, the public sale or distribution
thereof; provided however, by making the representations herein, the Buyer does
not agree to hold any of the Securities for any minimum or other specific term.
(b) Accredited Investor Status. The Buyer is an "accredited investor"
as that term is defined in Rule 501(a)(3) of Regulation D.
(c) Reliance on Exemptions. The Buyer understands that the Securities
are being offered and sold to it in reliance on specific exemptions from the
registration requirements of United States federal and state securities laws and
that the Company is relying in part upon the truth and accuracy of, and the
Buyer's compliance with, the representations, warranties, agreements,
acknowledgments and understandings of the Buyer set forth herein in order to
determine the availability of such exemptions and the eligibility of the Buyer
to acquire the Securities.
(d) Information. The Buyer has been furnished with all materials
relating to the business, finances and operations of the Company and materials
relating to the offer and sale of the Securities that have been reasonably
requested by the Buyer, including, without limitation, the SEC Documents (as
defined in Section 3(f) hereof). The Buyer understands that its investment in
the Securities involves a high degree of risk. The Buyer (i) is able to bear the
economic risk of an investment in the Securities including a total loss, (ii)
has such knowledge and experience in financial and business matters that it is
capable of evaluating the merits and risks of the proposed investment in the
Securities and (iii) has had an opportunity to ask questions of and receive
answers from the officers of the Company concerning the financial condition and
business of the Company and others matters related to an investment in the
Securities. Neither such inquiries nor any other due diligence investigations
conducted by the Buyer or its representatives shall modify, amend or affect the
Buyer's right to rely on the Company's representations and warranties contained
in Section 3 below. The Buyer has sought such accounting, legal and tax advice
as it has considered necessary to make an informed investment decision with
respect to its acquisition of the Securities.
(e) No Governmental Review. The Buyer understands that no United States
federal or state agency or any other government or governmental agency has
passed on or made any recommendation or endorsement of the Securities or the
fairness or suitability of the investment in the Securities nor have such
authorities passed upon or endorsed the merits of the offering of the
Securities.
5
(f) Transfer or Resale. The Buyer understands that except as provided
in the Registration Rights Agreement (as defined in Section 6(a) hereof): (i)
the Securities have not been and are not being registered under the 1933 Act or
any state securities laws, and may not be offered for sale, sold, assigned or
transferred unless (A) subsequently registered thereunder or (B) an exemption
exists permitting such Securities to be sold, assigned or transferred without
such registration; (ii) any sale of the Securities made in reliance on Rule 144
may be made only in accordance with the terms of Rule 144 and further, if Rule
144 is not applicable, any resale of the Securities under circumstances in which
the seller (or the person through whom the sale is made) may be deemed to be an
underwriter (as that term is defined in the 1933 Act) may require compliance
with some other exemption under the 1933 Act or the rules and regulations of the
SEC thereunder; and (iii) neither the Company nor any other person is under any
obligation to register the Securities under the 1933 Act or any state securities
laws or to comply with the terms and conditions of any exemption thereunder.
(g) Validity; Enforcement. This Agreement has been duly and validly
authorized, executed and delivered on behalf of the Buyer and is a valid and
binding agreement of the Buyer enforceable against the Buyer in accordance with
its terms, subject as to enforceability to general principles of equity and to
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and
other similar laws relating to, or affecting generally, the enforcement of
applicable creditors' rights and remedies.
(h) Residency. The Buyer is a resident of the State of Illinois.
(i) No Prior Short Selling. The Buyer represents and warrants to the
Company that at no time prior to the date of this Agreement has any of the
Buyer, its agents, associates, representatives or affiliates engaged in or
effected, in any manner whatsoever, directly or indirectly, any (i) "short sale"
(as such term is defined in Rule 3b-3 of the 1934 Act) of the Common Stock or
(ii) hedging transaction, which establishes a net short position with respect to
the Common Stock.
3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.
The Company represents and warrants to the Buyer that:
(a) Organization and Qualification. The Company and its "Subsidiaries"
(which for purposes of this Agreement means any entity in which the Company,
directly or indirectly, owns 50% or more of the voting stock or capital stock or
other similar equity interests) are corporations duly organized and validly
existing in good standing under the laws of the jurisdiction in which they are
incorporated, and have the requisite corporate power and authority to own their
properties and to carry on their business as now being conducted. Each of the
Company and its Subsidiaries is duly qualified as a foreign corporation to do
business and is in good standing in every jurisdiction in which its ownership of
property or the nature of the business conducted by it makes such qualification
necessary, except to the extent that the failure to be so qualified or be in
good standing could not reasonably be expected to have a Material Adverse
Effect. As used in this Agreement, "Material Adverse Effect" means any material
adverse effect on any of: (i) the business, properties, assets, operations,
results of operations or financial condition of the Company and its
Subsidiaries, if any, taken as a whole, (ii) the value of the Common Stock,
(iii) the transactions contemplated hereby or by the agreements and instruments
to be entered into in connection herewith or (iv) the authority or ability of
the Company to perform its obligations under the Transaction Documents (as
defined in Section 3(b) hereof). The Company has no Subsidiaries except as set
forth on Schedule 3(a).
(b) Authorization; Enforcement; Validity. (i) The Company has the
requisite corporate power and authority to enter into and perform its
obligations under this Agreement, the Registration
6
Rights Agreement (as defined in Section 6(a) hereof) and each of the other
agreements entered into by the parties hereto in connection with the
transactions contemplated by this Agreement (collectively, the "Transaction
Documents"), and to issue the Securities in accordance with the terms hereof and
thereof, (ii) the execution and delivery of the Transaction Documents by the
Company and the consummation by it of the transactions contemplated hereby and
thereby, including without limitation, the issuance of the Commitment Shares and
the reservation for issuance and the issuance of the Purchase Shares issuable
under this Agreement, have been duly authorized by the Company's Board of
Directors and no further consent or authorization is required by the Company,
its Board of Directors or its shareholders, (iii) this Agreement has been, and
each other Transaction Document shall be on the Commencement Date, duly executed
and delivered by the Company and (iv) this Agreement constitutes, and each other
Transaction Document upon its execution on behalf of the Company, shall
constitute, the valid and binding obligations of the Company enforceable against
the Company in accordance with their terms, except as such enforceability may be
limited by general principles of equity or applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or
affecting generally, the enforcement of creditors' rights and remedies.
(c) Capitalization. As of the date hereof, the authorized capital stock
of the Company consists of (i) 50 million shares of Common Stock, of which as of
the date hereof, 6,458,424 shares are issued and outstanding, no shares are held
as treasury shares, 1,164,198 shares are reserved for issuance pursuant to the
Company's stock option plans of which only approximately 31,998 shares remain
available for future grants under the plans and 1,190,896 shares are issuable
and reserved for issuance pursuant to securities (other than stock options
issued pursuant to the Company's stock option plans) exercisable or exchangeable
for, or convertible into, shares of Common Stock, and (ii) 1,100,000 shares of
Series A convertible preferred stock, $0.001 par value with a $13.00 per share
liquidation preference, of which as of the date hereof 351,588 shares are issued
and outstanding, and (iii) 2,000,000 shares of Series B convertible preferred
stock, $0.001 par value per share, of which as of the date hereof no shares are
issued and outstanding . All of such outstanding shares have been, or upon
issuance will be, validly issued and are fully paid and nonassessable. Except as
disclosed in Schedule 3(c), (i) no shares of the Company's capital stock are
subject to preemptive rights or any other similar rights or any liens or
encumbrances suffered or permitted by the Company, (ii) there are no outstanding
debt securities, (iii) there are no outstanding options, warrants, scrip, rights
to subscribe to, calls or commitments of any character whatsoever relating to,
or securities or rights convertible into, any shares of capital stock of the
Company or any of its Subsidiaries, or contracts, commitments, understandings or
arrangements by which the Company or any of its Subsidiaries is or may become
bound to issue additional shares of capital stock of the Company or any of its
Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities or rights
convertible into, any shares of capital stock of the Company or any of its
Subsidiaries, (iv) there are no agreements or arrangements under which the
Company or any of its Subsidiaries is obligated to register the sale of any of
their securities under the 1933 Act (except the Registration Rights Agreement),
(v) there are no outstanding securities or instruments of the Company or any of
its Subsidiaries which contain any redemption or similar provisions, and there
are no contracts, commitments, understandings or arrangements by which the
Company or any of its Subsidiaries is or may become bound to redeem a security
of the Company or any of its Subsidiaries, (vi) there are no securities or
instruments containing anti-dilution or similar provisions that will be
triggered by the issuance of the Securities as described in this Agreement and
(vii) the Company does not have any stock appreciation rights or "phantom stock"
plans or agreements or any similar plan or agreement. The Company has furnished
to the Buyer true and correct copies of the Company's Certificate of
Incorporation, as amended and as in effect on the date hereof (the "Certificate
of Incorporation"), and the Company's By-laws, as amended and as in effect on
the date hereof (the "By-laws"), and summaries of the terms of all securities
convertible into or exercisable for Common Stock, if any, and copies of any
documents containing the material rights of the holders thereof in respect
thereto.
7
(d) Issuance of Securities. The Commitment Shares have been duly
authorized and, upon issuance in accordance with the terms hereof, shall be (i)
validly issued, fully paid and non-assessable and (ii) free from all taxes,
liens and charges with respect to the issue thereof. 2,400,000 shares of Common
Stock have been duly authorized and reserved for issuance upon purchase under
this Agreement. Upon issuance and payment therefore in accordance with the terms
and conditions of this Agreement, the Purchase Shares shall be validly issued,
fully paid and nonassessable and free from all taxes, liens and charges with
respect to the issue thereof, with the holders being entitled to all rights
accorded to a holder of Common Stock.
(e) No Conflicts. Except as disclosed in Schedule 3(e), the execution,
delivery and performance of the Transaction Documents by the Company and the
consummation by the Company of the transactions contemplated hereby and thereby
(including, without limitation, the reservation for issuance and issuance of the
Purchase Shares) will not (i) result in a violation of the Certificate of
Incorporation, any Certificate of Designations, Preferences and Rights of any
outstanding series of preferred stock of the Company or the By-laws or (ii)
conflict with, or constitute a default (or an event which with notice or lapse
of time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any agreement,
indenture or instrument to which the Company or any of its Subsidiaries is a
party, or result in a violation of any law, rule, regulation, order, judgment or
decree (including federal and state securities laws and regulations and the
rules and regulations of the Principal Market applicable to the Company or any
of its Subsidiaries) or by which any property or asset of the Company or any of
its Subsidiaries is bound or affected, except in the case of conflicts, defaults
and violations under clause (ii), which could not reasonably be expected to
result in a Material Adverse Effect. Except as disclosed in Schedule 3(e),
neither the Company nor its Subsidiaries is in violation of any term of or in
default under its Certificate of Incorporation, any Certificate of Designation,
Preferences and Rights of any outstanding series of preferred stock of the
Company or By-laws or their organizational charter or by-laws, respectively.
Except as disclosed in Schedule 3(e), neither the Company nor any of its
Subsidiaries is in violation of any term of or is in default under any material
contract, agreement, mortgage, indebtedness, indenture, instrument, judgment,
decree or order or any statute, rule or regulation applicable to the Company or
its Subsidiaries, except for possible conflicts, defaults, terminations or
amendments which could not reasonably be expected to have a Material Adverse
Effect. The business of the Company and its Subsidiaries is not being conducted,
and shall not be conducted, in violation of any law, ordinance, regulation of
any governmental entity, except for possible violations, the sanctions for which
either individually or in the aggregate could not reasonably be expected to have
a Material Adverse Effect. Except as specifically contemplated by this Agreement
and as required under the 1933 Act, the Company is not required to obtain any
consent, authorization or order of, or make any filing or registration with, any
court or governmental agency or any regulatory or self-regulatory agency in
order for it to execute, deliver or perform any of its obligations under or
contemplated by the Transaction Documents in accordance with the terms hereof or
thereof. Except as disclosed in Schedule 3(e), all consents, authorizations,
orders, filings and registrations which the Company is required to obtain
pursuant to the preceding sentence shall be obtained or effected on or prior to
the Commencement Date. Except as disclosed in Schedule 3(e), the Company is not
and has not been since January 1, 1999, in violation of the listing requirements
of the Principal Market.
(f) SEC Documents; Financial Statements. Except as disclosed in
Schedule 3(f), since January 1, 1999, the Company has timely filed all reports,
schedules, forms, statements and other documents required to be filed by it with
the SEC pursuant to the reporting requirements of the Securities Exchange Act of
1934, as amended (the "1934 Act") (all of the foregoing filed prior to the date
hereof and all exhibits included therein and financial statements and schedules
thereto and documents incorporated by reference therein being hereinafter
referred to as the "SEC Documents"). As of their respective dates (except as
they have been correctly amended), the SEC Documents complied in all material
respects with the requirements of the 1934 Act and the rules and regulations of
the SEC
8
promulgated thereunder applicable to the SEC Documents, and none of the SEC
Documents, at the time they were filed with the SEC (except as they may have
been correctly amended), contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which
they were made, not misleading. As of their respective dates (except as they
have been correctly amended), the financial statements of the Company included
in the SEC Documents complied as to form in all material respects with
applicable accounting requirements and the published rules and regulations of
the SEC with respect thereto. Such financial statements have been prepared in
accordance with generally accepted accounting principles, consistently applied,
during the periods involved (except (i) as may be otherwise indicated in such
financial statements or the notes thereto or (ii) in the case of unaudited
interim statements, to the extent they may exclude footnotes or may be condensed
or summary statements) and fairly present in all material respects the financial
position of the Company as of the dates thereof and the results of its
operations and cash flows for the periods then ended (subject, in the case of
unaudited statements, to normal year-end audit adjustments).
(g) Absence of Certain Changes. Except as disclosed in Schedule 3(g),
since September 30, 2000, there has been no material adverse change in the
business, properties, operations, financial condition or results of operations
of the Company or its Subsidiaries. The Company has not taken any steps, and
does not currently expect to take any steps, to seek protection pursuant to any
bankruptcy law nor does the Company or any of its Subsidiaries have any
knowledge or reason to believe that its creditors intend to initiate involuntary
bankruptcy proceedings.
(h) Absence of Litigation. There is no action, suit, proceeding,
inquiry or investigation before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the
Company or any of its Subsidiaries, threatened in writing against or affecting
the Company, the Common Stock or any of the Company's Subsidiaries or any of the
Company's or the Company's Subsidiaries' officers or directors in their
capacities as such, which could reasonably be expected to have a Material
Adverse Effect. A description of each action, suit, proceeding, inquiry or
investigation before or by any court, public board, government agency,
self-regulatory organization or body which, as of the date of this Agreement, is
pending or threatened in writing against or affecting the Company, the Common
Stock or any of the Company's Subsidiaries or any of the Company's or the
Company's Subsidiaries' officers or directors in their capacities as such, is
set forth in Schedule 3(h).
(i) Acknowledgment Regarding Buyer's Status. The Company acknowledges
and agrees that the Buyer is acting solely in the capacity of arm's length
purchaser with respect to the Transaction Documents and the transactions
contemplated hereby and thereby. The Company further acknowledges that the Buyer
is not acting as a financial advisor or fiduciary of the Company (or in any
similar capacity) with respect to the Transaction Documents and the transactions
contemplated hereby and thereby and any advice given by the Buyer or any of its
representatives or agents in connection with the Transaction Documents and the
transactions contemplated hereby and thereby is merely incidental to the Buyer's
purchase of the Securities. The Company further represents to the Buyer that the
Company's decision to enter into the Transaction Documents has been based solely
on the independent evaluation by the Company and its representatives and
advisors.
(j) No General Solicitation. Neither the Company, nor any of its
affiliates, nor any person acting on its or their behalf, has engaged in any
form of general solicitation or general advertising (within the meaning of
Regulation D under the 1933 Act) in connection with the offer or sale of the
Securities.
(k) No Integrated Offering. Neither the Company, nor any of its
affiliates, nor any person acting on its or their behalf has, directly or
indirectly, made any offers or sales of any security or solicited any offers to
buy any security, under circumstances that would require registration of any of
the Securities
9
under the 1933 Act or cause this offering of the Securities to be integrated
with prior offerings by the Company for purposes of the 1933 Act or any
applicable shareholder approval provisions, including, without limitation, under
the rules and regulations of any exchange or automated quotation system on which
any of the securities of the Company are listed or designated, nor will the
Company or any of its Subsidiaries take any action or steps that would require
registration of any of the Securities under the 1933 Act or cause the offering
of the Securities to be integrated with other offerings.
(l) Dilutive Effect. The Company understands and acknowledges that the
number of Purchase Shares purchasable under this Agreement will increase in
certain circumstances. The Company further acknowledges that its obligation to
issue Purchase Shares under this Agreement in accordance with the term and
conditions hereof is absolute and unconditional regardless of the dilutive
effect that such issuance may have on the ownership interests of other
shareholders of the Company.
(m) Intellectual Property Rights. The Company and its Subsidiaries own
or possess adequate rights or licenses to use all material trademarks, trade
names, service marks, service mark registrations, service names, patents, patent
rights, copyrights, inventions, licenses, approvals, governmental
authorizations, trade secrets and rights necessary to conduct their respective
businesses as now conducted. Except as set forth on Schedule 3(m), none of the
Company's material trademarks, trade names, service marks, service mark
registrations, service names, patents, patent rights, copyrights, inventions,
licenses, approvals, government authorizations, trade secrets or other
intellectual property rights have expired or terminated, or, by the terms and
conditions thereof, could expire or terminate within two years from the date of
this Agreement. The Company and its Subsidiaries do not have any knowledge of
any infringement by the Company or its Subsidiaries of any material trademark,
trade name rights, patents, patent rights, copyrights, inventions, licenses,
service names, service marks, service mark registrations, trade secret or other
similar rights of others, or of any such development of similar or identical
trade secrets or technical information by others and, except as set forth on
Schedule 3(m), there is no claim, action or proceeding being made or brought
against, or to the Company's knowledge, being threatened against, the Company or
its Subsidiaries regarding trademark, trade name, patents, patent rights,
invention, copyright, license, service names, service marks, service mark
registrations, trade secret or other infringement, which could reasonably be
expected to have a Material Adverse Effect.
(n) Environmental Laws. The Company and its Subsidiaries (i) are in
compliance with any and all applicable foreign, federal, state and local laws
and regulations relating to the protection of human health and safety, the
environment or hazardous or toxic substances or wastes, pollutants or
contaminants ("Environmental Laws"), (ii) have received all permits, licenses or
other approvals required of them under applicable Environmental Laws to conduct
their respective businesses and (iii) are in compliance with all terms and
conditions of any such permit, license or approval, except where, in each of the
three foregoing clauses, the failure to so comply could not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect.
(o) Title. The Company and its Subsidiaries have good and marketable
title in fee simple to all real property and good and marketable title to all
personal property owned by them which is material to the business of the Company
and its Subsidiaries, in each case free and clear of all liens, encumbrances and
defects except such as are described in Schedule 3(o) or such as do not
materially affect the value of such property and do not interfere with the use
made and proposed to be made of such property by the Company and any of its
Subsidiaries. Any real property and facilities held under lease by the Company
and any of its Subsidiaries are held by them under valid, subsisting and
enforceable leases with such exceptions as are not material and do not interfere
with the use made and proposed to be made of such property and buildings by the
Company and its Subsidiaries.
10
(p) Insurance. The Company and each of its Subsidiaries are insured by
insurers of recognized financial responsibility against such losses and risks
and in such amounts as management of the Company believes to be prudent and
customary in the businesses in which the Company and its Subsidiaries are
engaged. Neither the Company nor any such Subsidiary has been refused any
insurance coverage sought or applied for and neither the Company nor any such
Subsidiary has any reason to believe that it will not be able to renew its
existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its
business at a cost that would not materially and adversely affect the condition,
financial or otherwise, or the earnings, business or operations of the Company
and its Subsidiaries, taken as a whole.
(q) Regulatory Permits. The Company and its Subsidiaries possess all
material certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct their
respective businesses, and neither the Company nor any such Subsidiary has
received any notice of proceedings relating to the revocation or modification of
any such certificate, authorization or permit.
(r) Tax Status. The Company and each of its Subsidiaries has made or
filed all federal and state income and all other material tax returns, reports
and declarations required by any jurisdiction to which it is subject (unless and
only to the extent that the Company and each of its Subsidiaries has set aside
on its books provisions reasonably adequate for the payment of all unpaid and
unreported taxes) and has paid all taxes and other governmental assessments and
charges that are material in amount, shown or determined to be due on such
returns, reports and declarations, except those being contested in good faith
and has set aside on its books provision reasonably adequate for the payment of
all taxes for periods subsequent to the periods to which such returns, reports
or declarations apply. There are no unpaid taxes in any material amount claimed
to be due by the taxing authority of any jurisdiction, and the officers of the
Company know of no basis for any such claim.
(s) Transactions With Affiliates. Except as set forth on Schedule 3(s)
and other than the grant or exercise of stock options disclosed on Schedule
3(c), none of the officers, directors, or employees of the Company is presently
a party to any transaction with the Company or any of its Subsidiaries (other
than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or
by, providing for rental of real or personal property to or from, or otherwise
requiring payments to or from any officer, director or such employee or, to the
knowledge of the Company, any corporation, partnership, trust or other entity in
which any officer, director, or any such employee has an interest or is an
officer, director, trustee or partner.
(t) Application of Takeover Protections. The Company and its board of
directors have taken or will take prior to the Commencement Date all necessary
action, if any, in order to render inapplicable any control share acquisition,
business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Certificate of
Incorporation or the laws of the state of its incorporation which is or could
become applicable to the Buyer as a result of the transactions contemplated by
this Agreement, including, without limitation, the Company's issuance of the
Securities and the Buyer's ownership of the Securities.
(u) Foreign Corrupt Practices. Neither the Company, nor any of its
Subsidiaries, nor any director, officer, agent, employee or other person acting
on behalf of the Company or any of its Subsidiaries has, in the course of its
actions for, or on behalf of, the Company, used any corporate funds for any
unlawful contribution, gift, entertainment or other unlawful expenses relating
to political activity; made any direct or indirect unlawful payment to any
foreign or domestic government official or employee from corporate funds;
violated or is in violation of any provision of the U.S. Foreign Corrupt
Practices
11
Act of 1977, as amended; or made any unlawful bribe, rebate, payoff, influence
payment, kickback or other unlawful payment to any foreign or domestic
government official or employee.
4. COVENANTS.
(a) Filing of Registration Statement. The Company shall within five (5)
Trading Days from the date hereof file a new registration statement covering the
sale of at least 2,400,000 Purchase Shares and 600,000 Commitment Shares. The
Buyer and its counsel shall have a reasonable opportunity to review and comment
upon such registration statement or amendment to such registration statement and
any related prospectus prior to its filing with the SEC. The Company shall use
its best efforts to have such registration statement or amendment declared
effective by the SEC at the earliest possible date.
(b) Blue Sky. The Company shall, on or before the Commencement Date,
take such action, if any, as the Company shall reasonably determine is necessary
in order to obtain an exemption for or to qualify the Commitment Shares and the
Purchase Shares for sale to the Buyer pursuant to this Agreement under
applicable securities or "Blue Sky" laws of the states of the United States, and
shall provide evidence of any such action so taken to the Buyer on or prior to
the Commencement Date. The Company shall make all filings and reports relating
to the offer and sale of the Commitment Shares and the Purchase Shares required
under applicable securities or "Blue Sky" laws of the states of the United
States following the Commencement Date.
(c) No Variable Priced Financing. Other than pursuant to this
Agreement, the Company agrees that beginning on the date of this Agreement and
ending on the date of termination of this Agreement (as provided in Section
11(k) hereof), neither the Company nor any of its Subsidiaries shall, without
the prior written consent of the Buyer, contract for any equity financing
(including any debt financing with an equity component) or issue any equity
securities of the Company or any Subsidiary or securities convertible or
exchangeable into or for equity securities of the Company or any Subsidiary
(including debt securities with an equity component) which, in any case (i) are
convertible into or exchangeable for an indeterminate number of shares of common
stock, (ii) are convertible into or exchangeable for Common Stock at a price
which varies with the market price of the Common Stock, (iii) directly or
indirectly provide for any "re-set" or adjustment of the purchase price,
conversion rate or exercise price after the issuance of the security, or (iv)
contain any "make-whole" provision based upon, directly or indirectly, the
market price of the Common Stock after the issuance of the security, in each
case, other than reasonable and customary anti-dilution adjustments for issuance
of shares of Common Stock at a price which is below the market price of the
Common Stock.
(d) Listing. The Company shall promptly secure the listing of all of
the Purchase Shares and Commitment Shares upon each national securities exchange
and automated quotation system, if any, upon which shares of Common Stock are
then listed (subject to official notice of issuance) and shall maintain, so long
as any other shares of Common Stock shall be so listed, such listing of all such
securities from time to time issuable under the terms of the Transaction
Documents. The Company shall maintain the Common Stock's authorization for
quotation on the Principal Market. Neither the Company nor any of its
Subsidiaries shall take any action that would be reasonably expected to result
in the delisting or suspension of the Common Stock on the Principal Market. The
Company shall promptly, and in no event later than the following Trading Day,
provide to the Buyer copies of any notices it receives from the Principal Market
regarding the continued eligibility of the Common Stock for listing on such
automated quotation system or securities exchange. The Company shall pay all
fees and expenses in connection with satisfying its obligations under this
Section.
12
(e) Limitation on Short Sales and Hedging Transactions. The Buyer
agrees that beginning on the date of this Agreement and ending on the date of
termination of this Agreement as provided in Section 11(k), the Buyer and its
agents, representatives and affiliates shall not in any manner whatsoever enter
into or effect, directly or indirectly, any (i) "short sale" (as such term is
defined in Rule 3b-3 of the 1934 Act) of the Common Stock or (ii) hedging
transaction, which establishes a net short position with respect to the Common
Stock; provided, however, that such restrictions shall not apply (i) if the
Buyer submits after a sale of shares of Common Stock a Purchase Notice entitling
the Buyer to receive a number of shares of Common Stock at least equal to the
number of shares so sold or (ii) if an Event of Default has occurred, including
any failure by the Company to timely issue any Purchase Shares required to be
issued pursuant to the terms of this Agreement.
(f) Limitation on Sales of Commitment Shares. The Buyer agrees that the
Buyer shall not transfer or sell the Commitment Shares (as defined in Section
7(b) hereof) until the earlier of 900 calendar days from the date hereof or date
on which this Agreement has been terminated, provided, however, that such
restrictions shall not apply: (i) in connection with any transfers to or among
affiliates (as defined in the Securities Exchange Act of 1934, as amended), (ii)
in connection with any pledge in connection with a bona fide loan or margin
account, or (iii) if an Event of Default has occurred, or any event which, after
notice and/or lapse of time, would become an Event of Default, including any
failure by the Company to timely issue Purchase Shares under this Agreement.
Notwithstanding the forgoing, the Buyer may transfer Commitment Shares to a
third party in order to settle a sale made by the Buyer where the Buyer
reasonably expects the Company to deliver Purchase Shares to the Buyer under
this Agreement so long as the Buyer maintains ownership of the same overall
number of shares of Common Stock by "replacing" the Commitment Shares so
transferred with Purchase Shares when the Purchase Shares are actually issued by
the Company to the Buyer.
(h) Due Diligence. The Buyer shall have the right, from time to time as
the Buyer may reasonably deem appropriate, to perform reasonable due diligence
on the Company during normal business hours. The Company and its officers and
employees shall reasonably cooperate with the Buyer in connection with any
reasonable request by the Buyer related to the Buyer's due diligence of the
Company.
5. TRANSFER AGENT INSTRUCTIONS.
All of the Purchase Shares and Commitment Shares to be issued under
this Agreement shall be issued without any restrictive legend.. The Company
shall issue irrevocable instructions to the Transfer Agent, and any subsequent
transfer agent, to issue Purchase Shares in the name of the Buyer or its
respective nominee(s), for the Purchase Shares (the "Irrevocable Transfer Agent
Instructions"). The Company warrants to the Buyer that no instruction other than
the Irrevocable Transfer Agent Instructions referred to in this Section 5, will
be given by the Company to the Transfer Agent with respect to the Purchase
Shares and that the Commitment Shares and the Purchase Shares shall otherwise be
freely transferable on the books and records of the Company as and to the extent
provided in this Agreement and the Registration Rights Agreement subject to the
provisions of Section 4(f) in the case of the Commitment Shares.
6. CONDITIONS TO THE COMPANY'S OBLIGATION TO COMMENCE
SALES OF SHARES OF COMMON STOCK.
The obligation of the Company hereunder to commence sales of the
Purchase Shares is subject to the satisfaction of each of the following
conditions on or before the Commencement Date, provided that
13
these conditions are for the Company's sole benefit and may be waived by the
Company at any time in its sole discretion by providing the Buyer with prior
written notice thereof:
(a) The Buyer shall have executed each of the Transaction Documents to
which it is a party and delivered the same to the Company including the
Registration Rights Agreement substantially in the form of Exhibit C hereto (the
"Registration Rights Agreement").
(b) Subject to the Company's compliance with Section 4(a), a
registration statement covering the sale of the 600,000 Commitment Shares and at
least 2,400,000 Purchase Shares shall have been declared effective under the
1933 Act by the SEC and no stop order with respect to the Registration Statement
shall be pending or threatened by the SEC.
(c) The representations and warranties of the Buyer shall be true and
correct in all material respects as of the date when made and as of the
Commencement Date as though made at that time (except for representations and
warranties that speak as of a specific date), and the Buyer shall have
performed, satisfied and complied in all material respects with the covenants,
agreements and conditions required by this Agreement to be performed, satisfied
or complied with by the Buyer at or prior to the Commencement Date.
7. CONDITIONS TO THE BUYER'S OBLIGATION TO COMMENCE
PURCHASES OF SHARES OF COMMON STOCK.
The obligation of the Buyer to commence purchases of Purchase Shares
under this Agreement is subject to the satisfaction, on or before the
Commencement Date, of each of the following conditions, provided that these
conditions are for the Buyer's sole benefit and may be waived by the Buyer at
any time in its sole discretion by providing the Company with prior written
notice thereof:
(a) The Company shall have executed each of the Transaction Documents
and delivered the same to the Buyer including the Registration Rights Agreement
substantially in the form of Exhibit C hereto.
(b) The Company shall have issued to the Buyer 600,000 shares of
Common Stock (the "Commitment Shares"). The number of Commitment Shares shall be
appropriately adjusted for any reorganization, recapitalization, non-cash
dividend, stock split or other similar transaction occurring on or prior to the
Commencement Date. The Commitment Shares shall be issued to the Buyer without
any restrictive legend.
(c) The Common Stock shall be authorized for quotation on the Principal
Market, trading in the Common Stock shall not have been within the last 365 days
suspended by the SEC or the Principal Market and the Purchase Shares and the
Commitment Shares shall be approved for listing upon the Principal Market.
(d) The Buyer shall have received the opinions of the Company's legal
counsel dated as of the Commencement Date in the form of Exhibit D attached
hereto.
(e) The representations and warranties of the Company shall be true and
correct in all material respects (except to the extent that any of such
representations and warranties is already qualified as to materiality in Section
3 above, in which case, such representations and warranties shall be true and
correct without further qualification) as of the date when made and as of the
Commencement Date as though made at that time (except for representations and
warranties that speak as of a specific date) and
14
the Company shall have performed, satisfied and complied with the covenants,
agreements and conditions required by the Transaction Documents to be performed,
satisfied or complied with by the Company at or prior to the Commencement Date.
The Buyer shall have received a certificate, executed by the CEO, President or
CFO of the Company, dated as of the Commencement Date, to the foregoing effect
in the form attached hereto as Exhibit E.
(f) The Board of Directors of the Company shall have adopted
resolutions in the form attached hereto as Exhibit F which shall be in full
force and effect without any amendment or supplement thereto as of the
Commencement Date.
(g) As of the Commencement Date, the Company shall have reserved out of
its authorized and unissued Common Stock, solely for the purpose of effecting
purchases of Purchase Shares hereunder, at least 2,400,000 shares of Common
Stock.
(h) The Irrevocable Transfer Agent Instructions, in the form of Exhibit
G attached hereto, shall have been delivered to and acknowledged in writing by
the Company and the Transfer Agent.
(i) The Company shall have delivered to the Buyer a certificate
evidencing the incorporation and good standing of the Company in the State of
Delaware issued by the Secretary of State of the State of Delaware as of a date
within ten (10) Trading Days of the Commencement Date.
(j) The Company shall have delivered to the Buyer a certified copy of
the Certificate of Incorporation as certified by the Secretary of State of the
State of Delaware within ten (10) Trading Days of the Commencement Date.
(k) The Company shall have delivered to the Buyer a secretary's
certificate executed by the Secretary of the Company, dated as of the
Commencement Date, in the form attached hereto as Exhibit H.
(l) A registration statement covering the sale of all of the 600,000
Commitment Shares and at least 2,4000,000 Purchase Shares shall have been
declared effective under the 1933 Act by the SEC and no stop order with respect
to the registration statement shall be pending or threatened by the SEC. The
Company shall have prepared and delivered to the Buyer a final form of
prospectus to be used by the Buyer in connection with any sales of any
Commitment Shares or any Purchase Shares. The Company shall have made all
filings under all applicable federal and state securities laws necessary to
consummate the issuance of the Commitment Shares and the Purchase Shares
pursuant to this Agreement in compliance with such laws.
(m) No Event of Default has occurred, or any event which, after notice
and/or lapse of time, would become an Event of Default has occurred.
(n) On or prior to the Commencement Date, the Company shall take all
necessary action, if any, and such actions as reasonably requested by the Buyer,
in order to render inapplicable any control share acquisition, business
combination, shareholder rights plan or poison pill (including any distribution
under a rights agreement) or other similar anti-takeover provision under the
Certificate of Incorporation or the laws of the state of its incorporation which
is or could become applicable to the Buyer as a result of the transactions
contemplated by this Agreement, including, without limitation, the Company's
issuance of the Securities and the Buyer's ownership of the Securities.
15
8. INDEMNIFICATION.
In consideration of the Buyer's execution and delivery of the
Transaction Documents and acquiring the Securities hereunder and in addition to
all of the Company's other obligations under the Transaction Documents, the
Company shall defend, protect, indemnify and hold harmless the Buyer and all of
its affiliates, shareholders, officers, directors, employees and direct or
indirect investors and any of the foregoing person's agents or other
representatives (including, without limitation, those retained in connection
with the transactions contemplated by this Agreement) (collectively, the
"Indemnitees") from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages, and expenses in
connection therewith (irrespective of whether any such Indemnitee is a party to
the action for which indemnification hereunder is sought), and including
reasonable attorneys' fees and disbursements (the "Indemnified Liabilities"),
incurred by any Indemnitee as a result of, or arising out of, or relating to (a)
any misrepresentation or breach of any representation or warranty made by the
Company in the Transaction Documents or any other certificate, instrument or
document contemplated hereby or thereby, (b) any breach of any covenant,
agreement or obligation of the Company contained in the Transaction Documents or
any other certificate, instrument or document contemplated hereby or thereby, or
(c) any cause of action, suit or claim brought or made against such Indemnitee
and arising out of or resulting from the execution, delivery, performance or
enforcement of the Transaction Documents or any other certificate, instrument or
document contemplated hereby or thereby, other than with respect to Indemnified
Liabilities which directly and primarily result from the gross negligence or
willful misconduct of the Indemnitee. To the extent that the foregoing
undertaking by the Company may be unenforceable for any reason, the Company
shall make the maximum contribution to the payment and satisfaction of each of
the Indemnified Liabilities which is permissible under applicable law.
9. EVENTS OF DEFAULT.
An "Event of Default" shall be deemed to have occurred at any time as
any of the following events occurs:
(a) while any registration statement is required to be maintained
effective pursuant to the terms of the Registration Rights Agreement, the
effectiveness of such registration statement lapses for any reason (including,
without limitation, the issuance of a stop order) or is unavailable to the Buyer
for sale of all of the Registrable Securities (as defined in the Registration
Rights Agreement) in accordance with the terms of the Registration Rights
Agreement, and such lapse or unavailability continues for a period of ten (10)
consecutive Trading Days or for more than an aggregate of thirty (30) Trading
Days in any 365-day period;
(b) the suspension from trading or failure of the Common Stock to be
listed on the Principal Market for a period of ten (10) consecutive Trading Days
or for more than an aggregate of thirty (30) Trading Days in any 365-day period;
(c) the failure of the Company or the Common Stock to fully meet the
requirements for continued listing on the Principal Market for a period of
thirty (30) consecutive Trading Days;
(d) the Company's or the Transfer Agent's notice, verbal or written, to
the Buyer, including by way of public announcement, at any time, of its
intention not to comply with a proper request for purchase of Purchase Shares
under this Agreement that is tendered in accordance with the provisions of this
Agreement, or the failure of the Company to deliver a Company Confirmation of
Purchase Notice to the Buyer and to the Transfer Agent in accordance with the
provisions of this Agreement within two (2) Trading Days after the receipt by
the Company of a Purchase Notice (subject to extension in accordance with
Section 1(e)(iii) for a good faith dispute made in accordance with the terms of
Section 1(e)(iii)); or
16
the failure for any reason by the Transfer Agent to issue Purchase Shares to the
Buyer within five (5) Trading Days after the applicable Purchase Date;
(e) if at any time after the Commencement Date, the "Exchange Cap" is
reached (the "Exchange Cap" shall be deemed to be reached at such time if, upon
submission of a Purchase Notice under this Agreement, the issuance of such
shares of Common Stock would exceed that number of shares of Common Stock which
the Company may issue under this Agreement without breaching the Company's
obligations under the rules or regulations of the Principal Market);
(f) the Company breaches any representation, warranty, covenant or
other term or condition under any Transaction Document if such breach could have
a Material Adverse Effect and except, in the case of a breach of a covenant
which is reasonably curable, only if such breach continues for a period of at
least ten (10) Trading Days;
(g) except as set forth on Schedule 9(g), any payment default under any
contract whatsoever or any acceleration prior to maturity of any mortgage,
indenture, contract or instrument under which there may be issued or by which
there may be secured or evidenced any indebtedness for money borrowed by the
Company or for money borrowed the repayment of which is guaranteed by the
Company, whether such indebtedness or guarantee now exists or shall be created
hereafter, which in any case, is in excess of $1,000,000;
(h) if any Person commences a proceeding against the Company pursuant
to or within the meaning of any Bankruptcy Law;
(i) if the Company pursuant to or within the meaning of any Bankruptcy
Law; (A) commences a voluntary case, (B) consents to the entry of an order for
relief against it in an involuntary case, (C) consents to the appointment of a
Custodian of it or for all or substantially all of its property, (D) makes a
general assignment for the benefit of its creditors, (E) becomes insolvent, or
(F) is generally unable to pay its debts as the same become due; or
(j) a court of competent jurisdiction enters an order or decree under
any Bankruptcy Law that (A) is for relief against the Company in an involuntary
case, (B) appoints a Custodian of the Company or for all or substantially all of
its property, or (C) orders the liquidation of the Company or any Subsidiary.
In addition to any other rights and remedies under applicable law and this
Agreement, including the Buyer termination rights under Section 11(k) hereof, so
long as an Event of Default has occurred and is continuing, or if any event
which, after notice and/or lapse of time, would become an Event of Default, has
occurred and is continuing, the Buyer shall not be obligated to purchase any
shares of Common Stock under this Agreement. If pursuant to or within the
meaning of any Bankruptcy Law, the Company commences a voluntary case or any
Person commences a proceeding against the Company, a Custodian is appointed for
the Company or for all or substantially all of its property, or the Company
makes a general assignment for the benefit of its creditors, (any of which would
be an Event of Default as described in Sections 9(h), 9(i) and 9(j) hereof) this
Agreement shall automatically terminate without any liability or payment to the
Company without further action or notice by any Person. No such termination of
this Agreement under Section 11(k)(i) shall affect the Company's or the Buyer's
obligations under this Agreement with respect to pending purchases and the
Company and the Buyer shall complete their respective obligations with respect
to any pending purchases under this Agreement.
17
10. CERTAIN DEFINED TERMS.
For purposes of this Agreement, the following terms shall have the
following meanings:
(a) "1933 Act" means the Securities Act of 1933, as amended.
(b) "Available Amount" means initially Six Million Dollars ($6,000,000)
in the aggregate, which amount shall be reduced by the Purchase Amount each time
the Buyer purchases shares of Common Stock pursuant to Section 1 hereof.
(c) "Bankruptcy Law" means Title 11, U.S. Code, or any similar federal
or state law for the relief of debtors.
(d) "Closing Bid Price" means, for any security as of any date, the
last closing bid price for such security on the Principal Market as reported by
Bloomberg Financial Markets ("Bloomberg"), or, if the Principal Market is not
the principal securities exchange or trading market for such security, the last
closing bid price of such security on the principal securities exchange or
trading market where such security is listed or traded as reported by Bloomberg.
(e) "Closing Sale Price" means, for any security as of any date, the
last closing trade price for such security on the Principal Market as reported
by Bloomberg, or, if the Principal Market is not the principal securities
exchange or trading market for such security, the last closing trade price of
such security on the principal securities exchange or trading market where such
security is listed or traded as reported by Bloomberg.
(f) "Custodian" means any receiver, trustee, assignee, liquidator or
similar official under any Bankruptcy Law.
(g) "Fixed Purchase Price" means $20.00, appropriately adjusted for any
reorganization, recapitalization, non-cash dividend, stock split or other
similar transaction.
(h) [Intentionally Omitted.]
(i) "Mandatory Purchase Rights" means the mandatory purchase rights of
the Company pursuant to Section 1(c).
(j) "Maturity Date" means the date that is 900 calendar days (30
Monthly Periods) from the Commencement Date which such date may be extended by
up to an additional six (6) months by the Company, in its sole discretion, by
written notice to the Buyer].
(k) "Monthly Base Amount" means Two Hundred Thousand Dollars ($200,000)
per Monthly Period.
(l) "Monthly Period" means each successive 30 calendar day period
commencing with the Commencement Date.
(m) "Person" means an individual or entity including any limited
liability company, a partnership, a joint venture, a corporation, a trust, an
unincorporated organization and a government or any department or agency
thereof.
(n) "Principal Market" means the Nasdaq SmallCap Market,
18
(o) "Purchase Amount" means the portion of the Available Amount
submitted in a Purchase Notice to be used to purchase Common Stock pursuant to
Section 1 hereof.
(p) "Purchase Date" means the actual date that the Buyer submits a
Purchase Notice to the Company to purchase Common Stock hereunder so long as the
Buyer shall transmit by facsimile (or otherwise deliver) to the Company on or
prior to 11:59 p.m., Central Time on such date.
(q) "Purchase Price" means, as of any Purchase Date or other date of
determination, the lower of the (A) Fixed Purchase Price and (B) the Variable
Purchase Price, each in effect as of such date.
(r) "Sale Price" means, for any security as of any date, any trade
price for such security on the Principal Market as reported by Bloomberg, or, if
the Principal Market is not the principal securities exchange or trading market
for such security, the trade price of such security on the principal securities
exchange or trading market where such security is listed or traded as reported
by Bloomberg.
(s) "SEC" means the United States Securities and Exchange Commission.
(t) "Trading Day" means any day on which the Principal Market is open
for customary trading.
(u) "Variable Purchase Price" means, as of any Purchase Date or other
date of determination, the lower of: (A) the lowest Sale Price of the Common
Stock on the Purchase Date or such other date of determination or (B) the
arithmetic average of any three (3) Closing Bid Prices for the Common Stock,
selected by the Buyer, during the twelve (12) consecutive Trading Days ending on
the Trading Day immediately preceding such Purchase Date or other date of
determination (to be appropriately adjusted for any reorganization,
recapitalization, non-cash dividend, stock split or other similar transaction).
11. MISCELLANEOUS.
(a) Governing Law; Jurisdiction; Jury Trial. The corporate laws of the
State of Delaware shall govern all issues concerning the relative rights of the
Company and its shareholders. All other questions concerning the construction,
validity, enforcement and interpretation of this Agreement and the other
Transaction Documents shall be governed by the internal laws of the State of
Illinois, without giving effect to any choice of law or conflict of law
provision or rule (whether of the State of Illinois or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the
State of Illinois. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of Chicago, for
the adjudication of any dispute hereunder or under the other Transaction
Documents or in connection herewith or therewith, or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not
personally subject to the jurisdiction of any such court, that such suit, action
or proceeding is brought in an inconvenient forum or that the venue of such
suit, action or proceeding is improper. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such
suit, action or proceeding by mailing a copy thereof to such party at the
address for such notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve
process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY
RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS
AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.
19
(b) Counterparts. This Agreement may be executed in two or more
identical counterparts, all of which shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each
party and delivered to the other party; provided that a facsimile signature
shall be considered due execution and shall be binding upon the signatory
thereto with the same force and effect as if the signature were an original, not
a facsimile signature.
(c) Headings. The headings of this Agreement are for convenience of
reference and shall not form part of, or affect the interpretation of, this
Agreement.
(d) Severability. If any provision of this Agreement shall be invalid
or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in
that jurisdiction or the validity or enforceability of any provision of this
Agreement in any other jurisdiction.
(e) Entire Agreement; Amendments. This Agreement supersedes all other
prior oral or written agreements between the Buyer, the Company, their
affiliates and persons acting on their behalf with respect to the matters
discussed herein, and this Agreement, the other Transaction Documents and the
instruments referenced herein contain the entire understanding of the parties
with respect to the matters covered herein and therein and, except as
specifically set forth herein or therein, neither the Company nor the Buyer
makes any representation, warranty, covenant or undertaking with respect to such
matters. No provision of this Agreement may be amended other than by an
instrument in writing signed by the Company and the Buyer, and no provision
hereof may be waived other than by an instrument in writing signed by the party
against whom enforcement is sought.
(f) Notices. Any notices, consents, waivers or other communications
required or permitted to be given under the terms of this Agreement must be in
writing and will be deemed to have been delivered: (i) upon receipt, when
delivered personally; (ii) upon receipt, when sent by facsimile (provided
confirmation of transmission is mechanically or electronically generated and
kept on file by the sending party); or (iii) one Trading Day after deposit with
a nationally recognized overnight delivery service, in each case properly
addressed to the party to receive the same. The addresses and facsimile numbers
for such communications shall be:
If to the Company:
Atlantic Technology Ventures, Inc.
150 Broadway, Suite 1009
New York, NY 10038
Telephone: 212-267-2503
Facsimile: 212-267-2159
Attention: Frederic P. Zotos
With a copy to:
Kramer Levin Naftalis & Frankel LLP
919 Third Avenue
New York, NY 10022
Telephone: 212-715-9100
Facsimile: 212-715-8000
Attention: Ezra G. Levin, Esq.
If to the Buyer:
Fusion Capital Fund II, LLC
222 Merchandise Mart Plaza, Suite 9-112
Chicago, IL 60654
Telephone: 312-644-6644
Facsimile: 312-644-6244
Attention: Steven G. Martin
20
If to the Transfer Agent:
Continental Stock Transfer & Trust Company
2 Broadway
New York, NY 10004
Telephone: 212-509-4000, ext. 204
Facsimile: 212-616-7616
Attention: William Seegraber
or at such other address and/or facsimile number and/or to the attention of such
other person as the recipient party has specified by written notice given to
each other party three (3) Trading Days prior to the effectiveness of such
change. Written confirmation of receipt (A) given by the recipient of such
notice, consent, waiver or other communication, (B) mechanically or
electronically generated by the sender's facsimile machine containing the time,
date, and recipient facsimile number or (C) provided by a nationally recognized
overnight delivery service, shall be rebuttable evidence of personal service,
receipt by facsimile or receipt from a nationally recognized overnight delivery
service in accordance with clause (i), (ii) or (iii) above, respectively.
(g) Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of the parties and their respective successors and assigns.
The Company shall not assign this Agreement or any rights or obligations
hereunder without the prior written consent of the Buyer, including by merger or
consolidation. The Buyer may not assign its rights under this Agreement without
the consent of the Company, other than to an affiliate of the Buyer controlled
by Steven G. Martin or Joshua B. Scheinfeld.
(h) No Third Party Beneficiaries. This Agreement is intended for the
benefit of the parties hereto and their respective permitted successors and
assigns, and is not for the benefit of, nor may any provision hereof be enforced
by, any other person.
(i) Publicity. The Buyer shall have the right to approve before
issuance any press releases or any other public disclosure (including any
filings with the SEC) with respect to the transactions contemplated hereby;
provided, however, that the Company shall be entitled, without the prior
approval of any Buyer, to make any press release or other public disclosure
(including any filings with the SEC) with respect to such transactions as is
required by applicable law and regulations (although the Buyer shall be
consulted by the Company in connection with any such press release or other
public disclosure prior to its release and shall be provided with a copy
thereof).
(j) Further Assurances. Each party shall do and perform, or cause to be
done and performed, all such further acts and things, and shall execute and
deliver all such other agreements, certificates, instruments and documents, as
the other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.
(k) Termination. This Agreement may be terminated only as follows:
(i) By the Buyer any time an Event of Default exists without
any liability or payment to the Company. However, if pursuant to or
within the meaning of any Bankruptcy Law, the Company commences a
voluntary case or any Person commences a proceeding against
21
the Company, a Custodian is appointed for the Company or for all or
substantially all of its property, or the Company makes a general
assignment for the benefit of its creditors, (any of which would be an
Event of Default as described in Sections 9(h), 9(i) and 9(j) hereof)
this Agreement shall automatically terminate without any liability or
payment to the Company without further action or notice by any Person.
No such termination of this Agreement under this Section 11(k)(i) shall
affect the Company's or the Buyer's obligations under this Agreement
with respect to pending purchases and the Company and the Buyer shall
complete their respective obligations with respect to any pending
purchases under this Agreement.
(ii) In the event that the Commencement shall not have
occurred, the Company shall have the option to terminate this Agreement
for any reason or for no reason without liability of any party to any
other party. If this Agreement is terminated pursuant to this Section
11(k)(ii), the Company shall issue to the Buyer the Commitment Shares
immediately prior to the termination hereof.
(iii) In the event that the Commencement shall not have
occurred on or before May 31, 2001, due to the failure to satisfy the
conditions set forth in Sections 6 and 7 above with respect to the
Commencement (and the nonbreaching party's failure to waive such
unsatisfied condition(s)), the nonbreaching party shall have the option
to terminate this Agreement at the close of business on such date or
thereafter without liability of any party to any other party. If this
Agreement is terminated pursuant to this Section 11(k)(iii) prior to
the Commencement other than solely as a result of any material breach
of the Buyer's obligation hereunder, the Company shall issue to the
Buyer the Commitment Shares immediately upon the termination hereof.
(iv) If by the Maturity Date, for any reason or for no reason
the full Available Amount under this Agreement has not been purchased
as provided for in Section 1 of this Agreement, by the Buyer without
any liability or payment to the Company.
(v) At any time after the Commencement Date, and so long as
the Company has provided appropriate notice as described below, if
during any ten (10) consecutive Trading Days the Closing Sale Price of
the Common Stock is below the Fixed Purchase Price for each of such ten
(10) Trading Days, the Company shall have three (3) Trading Days to
give written notice (a "Company Termination Notice") to the Buyer
electing to terminate this Agreement without any liability or payment
to the Buyer. The Company Termination Notice shall not be effective
until three (3) Trading Days after it has been received by the Buyer.
Any Purchase Notices submitted by the Buyer which have a Purchase Date
on or prior to the third (3rd) Trading Day after receipt by the Buyer
of the Company Termination Notice, must be honored by the Company as
otherwise provided herein.
(vi) This Agreement shall automatically terminate on the date
that the Company sells and the Buyer purchases Six Million Dollars
($6,000,000) of Common Stock as provided herein, without any action or
notice on the part of any party.
Except as set forth in Sections 11(k)(i) and 11(k)(vi), any termination of this
Agreement pursuant to this Section 11(k) shall be effected by written notice
from the Company to the Buyer, or the Buyer to the Company, as the case may be,
setting forth the basis for the termination hereof. The representations and
warranties of the Company and the Buyer contained in Sections 2 and 3 hereof,
the indemnification provisions set forth in Section 8 hereof and the agreements
and covenants set forth in Section 1(e) (v) and Section 11, shall survive the
Commencement and any termination of this Agreement. No termination of this
Agreement shall effect the Company's or the Buyer's obligations under this
Agreement with respect
22
to pending purchases and the Company and the Buyer shall complete their
respective obligations with respect to any pending purchases under this
Agreement.
(l) No Financial Advisor, Placement Agent, Broker or Finder. The
Company represents and warrants to the Buyer that it has not engaged any
financial advisor, placement agent, broker or finder in connection with the
transactions contemplated hereby. The Buyer represents and warrants to the
Company that it has not engaged any financial advisor, placement agent, broker
or finder in connection with the transactions contemplated hereby. The Company
shall be responsible for the payment of any fees or commissions, if any, of any
financial advisor, placement agent, broker or finder relating to or arising out
of the transactions contemplated hereby. The Company shall pay, and hold the
Buyer harmless against, any liability, loss or expense (including, without
limitation, attorneys' fees and out of pocket expenses) arising in connection
with any such claim.
(m) No Strict Construction. The language used in this Agreement is the
language chosen by the parties to express their mutual intent, and no rules of
strict construction will be applied against any party.
(n) Remedies, Other Obligations, Breaches and Injunctive Relief. The
Buyer's remedies provided in this Agreement shall be cumulative and in addition
to all other remedies available to the Buyer under this Agreement, at law or in
equity (including a decree of specific performance and/or other injunctive
relief), no remedy of the Buyer contained herein shall be deemed a waiver of
compliance with the provisions giving rise to such remedy and nothing herein
shall limit the Buyer's right to pursue actual damages for any failure by the
Company to comply with the terms of this Agreement. The Company acknowledges
that a breach by it of its obligations hereunder will cause irreparable harm to
the Buyer and that the remedy at law for any such breach may be inadequate. The
Company therefore agrees that, in the event of any such breach or threatened
breach, the Buyer shall be entitled, in addition to all other available
remedies, to an injunction restraining any breach, without the necessity of
showing economic loss and without any bond or other security being required.
(o) Changes to the Terms of this Agreement. This Agreement and any
provision hereof may only be amended by an instrument in writing signed by the
Company and the Buyer. The term "Agreement" and all reference thereto, as used
throughout this instrument, shall mean this instrument as originally executed,
or if later amended or supplemented, then as so amended or supplemented.
(p) Enforcement Costs. If: (i) this Agreement is placed by the Buyer in
the hands of an attorney for enforcement or is enforced by the Buyer through any
legal proceeding; or (ii) an attorney is retained to represent the Buyer in any
bankruptcy, reorganization, receivership or other proceedings affecting
creditors' rights and involving a claim under this Agreement; or (iii) an
attorney is retained to represent the Buyer in any other proceedings whatsoever
in connection with this Agreement, then the Company shall pay to the Buyer, as
incurred by the Buyer, all reasonable costs and expenses including attorneys'
fees incurred in connection therewith, in addition to all other amounts due
hereunder.
(q) Failure or Indulgence Not Waiver. No failure or delay in the
exercise of any power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such power, right or
privilege preclude other or further exercise thereof or of any other right,
power or privilege.
* * * * *
23
IN WITNESS WHEREOF, the Buyer and the Company have caused this Common
Stock Purchase Agreement to be duly executed as of the date first written above.
THE COMPANY:
ATLANTIC TECHNOLOGY VENTURES, INC.
By: /s/ Frederic P. Zotos
-------------------------------
Name: Frederic P. Zotos
Title: President
BUYER:
FUSION CAPITAL FUND II, LLC
BY: FUSION CAPITAL PARTNERS, LLC
BY: SGM HOLDINGS CORP.
By: /s/ Steven G. Martin
-------------------------------
Name: Steven G. Martin
Title: President
24
SCHEDULES
Schedule 3(a) Subsidiaries
Schedule 3(c) Capitalization
Schedule 3(e) Conflicts
Schedule 3(f) 1934 Act Filings
Schedule 3(g) Material Changes
Schedule 3(h) Litigation
Schedule 3(m) Intellectual Property
Schedule 3(o) Liens
Schedule 3(s) Certain Transactions
Schedule 9(g) Certain Indebtedness
EXHIBITS
Exhibit A Form of Purchase Notice
Exhibit B Form of Company Confirmation of Purchase Notice
Exhibit C Form of Registration Rights Agreement
Exhibit D Form of Company Counsel Opinion
Exhibit E Form of Officer's Certificate
Exhibit F Form of Resolutions of Board of Directors of the Company
Exhibit G Form of Irrevocable Transfer Agent Instructions
Exhibit H Form of Secretary's Certificate
DISCLOSURE SCHEDULES
Schedule 3(a) - Subsidiaries
Schedule 3(c) - Capitalization
Schedule 3(e) - No Conflicts
Schedule 3(f) - 1934 Act Filings
Schedule 3(g) - Absence of Certain Changes
Schedule 3(h) - Litigation
Schedule 3(m) - Intellectual Property Rights
Schedule 3(o) - Title
Schedule 3(s) - Transactions with Affiliates
EXHIBIT A
FORM OF PURCHASE NOTICE
Reference is made to the Common Stock Purchase Agreement (the "Common
Stock Purchase Agreement") between __________ (the "Company") and FUSION CAPITAL
FUND II, LLC dated __________. In accordance with and pursuant to the Common
Stock Purchase Agreement, the undersigned hereby elects to purchase shares of
common stock, par value $____ per share (the "Common Stock"), of the Company for
the Available Amount indicated below of as of the date specified below.
Purchase Date: ___________________________
Monthly Period Dates: ___________________________
Initial Available Amount: $__________
Monthly Base Amount: $__________
Remaining Available Amount
prior to this purchase: $__________________________
Remaining Monthly Base Amount
prior to this purchase: $__________________________
Available Amount to be purchased: $__________________________
Remaining Available Amount
after this purchase: $__________________________
Remaining Monthly Base Amount
after this purchase: $__________________________
Please confirm the following information:
Purchase Price per share: $__________________________
Fixed Purchase Price of $____
Low Sale Price on Date Hereof
Average of ____ Closing Bid Prices for _______($___), _______($___),
_______($___).
Number of shares of Common Stock to be issued:
Please issue the shares of Common Stock in the following name and to the
following address:
Issue to: ____________________________
Authorized Signature: ____________________________
Name:_______________________
Title:______________________
Phone #:____________________
Broker DTC Participant Code: ________________
Account Number* : ________________
* Note that receiving broker must initiate transaction on DWAC System.
EXHIBIT B
FORM OF COMPANY CONFIRMATION OF PURCHASE NOTICE
Reference is made to the Common Stock Purchase Agreement (the "Common
Stock Purchase Agreement") between _______ (the "Company") and FUSION CAPITAL
FUND II, LLC dated ________. In accordance with and pursuant to the Common Stock
Purchase Agreement, the undersigned hereby confirms and authorizes the issuance
of shares of common stock, par value $___ per share (the "Common Stock") of the
Company, in connection with the Purchase Notice (as defined in the Common Stock
Purchase Agreement) attached hereto. Specifically, the Company hereby confirms
the following information:
Purchase Date: ____________________________
Monthly Period Dates: ____________________________
Initial Available Amount: $___________
Monthly Base Amount: $___________
Remaining Available Amount
prior to this purchase: $___________________________
Remaining Monthly Base Amount
prior to this purchase: $___________________________
Available Amount to be purchased: $___________________________
Remaining Available Amount
after this purchase: $___________________________
Remaining Monthly Base Amount
after this purchase: $___________________________
Purchase Price per share: $___________________________
Number of shares of Common
Stock to be issued: ____________________________
The shares of Common Stock shall be issued in the name and to the address as set
forth in the applicable Purchase Notice.
Authorized Signature
-----------------------------
Name:
-----------------------
Title:
----------------------
Phone #:
---------------------
Fax #:
-----------------------
EXHIBIT C
FORM OF REGISTRATION RIGHTS AGREEMENT
[Sent separately]
EXHIBIT D
FORM OF COMPANY COUNSEL OPINION
Capitalized terms used herein but not defined herein have the meaning
set forth in the Common Stock Purchase Agreement. Based on the foregoing, and
subject to the assumptions and qualifications set forth herein, we are of the
opinion that:
1. The Company is a corporation existing and in good standing under the laws
of the State of _________. The Company is qualified to do business as a
foreign corporation and is in good standing in the States of ___________.
2. The Company has the corporate power to execute and deliver, and perform
its obligations under, each Transaction Document to which it is a party.
The Company has the corporate power to conduct its business as, to the
best of our knowledge, it is now conducted, and to own and use the
properties owned and used by it.
3. The execution, delivery and performance by the Company of the Transaction
Documents to which it is a party have been duly authorized by all
necessary corporate action on the part of the Company. The execution and
delivery of the Transaction Documents by the Company, the performance of
the obligations of the Company thereunder and the consummation by it of
the transactions contemplated therein have been duly authorized and
approved by the Company's Board of Directors and no further consent,
approval or authorization of the Company, its Board of Directors or its
stockholders is required. The Transaction Documents to which the Company
is a party have been duly executed and delivered by the Company and are
the valid and binding obligations of the Company, enforceable against the
Company in accordance with their terms except as such enforceability may
be limited by general principals of equity or applicable bankruptcy,
insolvency, liquidation or similar laws relating to, or affecting
creditor's rights and remedies.
4. The issuance and sale of the Commitment Shares and the Purchase Shares
pursuant to the terms and conditions of the Common Stock Purchase
Agreement has been duly authorized. ______ shares of Common Stock have
been properly reserved for issuance as Purchase Shares in accordance with
the Common Stock Purchase Agreement. The Commitment Shares have been
issued in accordance with the Common Stock Purchase Agreement and are
validly issued, fully paid and non-assessable and free of all taxes,
liens, charges, restrictions, rights of first refusal and preemptive
rights. When issued and paid for in accordance with the Common Stock
Purchase Agreement, the Purchase Shares shall be validly issued, fully
paid and non-assessable and free of all taxes, liens, charges,
restrictions, rights of first refusal and preemptive rights. To our
knowledge, the execution and delivery of the Registration Rights Agreement
do not, and the performance by the Company of its obligations thereunder
shall not, give rise to any rights of any other person for the
registration under the Securities Act of any shares of Common Stock or
other securities of the Company which have not been waived.
5. The execution, delivery and performance by the Company of the Transaction
Documents, the consummation by the Company of the transactions
contemplated thereby including the offering, sale and issuance of the
Commitment Shares and the Purchase Shares in accordance with the terms and
conditions of the Common Stock Purchase Agreement, and fulfillment and
compliance with terms of the Transaction Documents, does not and shall
not: (i) conflict with, constitute a breach of or default (or an event
which, with the giving of notice or lapse of time or both, constitutes or
could constitute a breach or a default), under (a) the Certificate of
Incorporation or the Bylaws of the Company, (b) any
material agreement, note, lease, mortgage, deed or other material
instrument to which to our knowledge the Company is a party or by which
the Company or any of its assets are bound, (ii) result in any violation
of any statute, law, rule or regulation applicable to the Company, or
(iii) to our knowledge, violate any order, writ, injunction or decree
applicable to the Company or any of its subsidiaries.
6. As of the date hereof, the authorized capital stock of the Company
consists of (i) ___________ shares of Common Stock, par value $_____ per
share, of which to our knowledge ___________ shares are issued and
outstanding, and (ii) ________ shares of preferred stock, par value $_____
per share of which to our knowledge ________ shares are issued and
outstanding. Except as set forth on Schedule 3(c) of the Common Stock
Purchase Agreement, to our knowledge, there are no outstanding shares of
capital stock or other securities convertible into or exchangeable or
exercisable for shares of the capital stock of the Company.
7. The Common Stock is registered pursuant to Section 12(g) of the Exchange
Act. To our knowledge, since January 1, 1999, the Company has been in
compliance with the reporting requirements of the Exchange Act applicable
to it. To our knowledge, since January 1, 1999, the Company has not
received any written notice from the Principal Market stating that the
Company has not been in compliance with any of the rules and regulations
(including the requirements for continued listing) of the Principal
Market.
8. Other then which has been obtained and completed prior to the date hereof,
no authorization, approval, consent, filing or other order of any federal
or state governmental body, regulatory agency, self-regulatory
organization or stock exchange or market, or the shareholders of the
Company, or any court, or, to our knowledge, any third party, is required
to be obtained by the Company to enter into and perform its obligations
under the Transaction Documents or for the issuance and sale of the
Commitment Shares or the Purchase Shares as contemplated by the
Transaction Documents.
We further advise you that to our knowledge, except as disclosed on
Schedule 3(h) in the Common Stock Purchase Agreement, there is no action, suit,
proceeding, inquiry or investigation before or by any court, public board or
body, any governmental agency, any stock exchange or market, or self-regulatory
organization, which has been threatened in writing or which is currently pending
against the Company, any of its subsidiaries, any officers or directors of the
Company or any of its subsidiaries or any of the properties of the Company or
any of its subsidiaries.
In addition, we have participated in the preparation of the
Registration Statement (SEC File #________) covering the sale of the Purchase
Shares and the Commitment Shares, including the prospectus dated ____________,
contained therein, and have participated in conferences with officers and other
representatives of the Company (including the Company's independent auditors)
during which the contents of the Registration Statement and related matters were
discussed and reviewed and, although we are not passing upon and do not assume
any responsibility for the accuracy, completeness or fairness of the statements
contained in the Registration Statement, on the basis of the information that
was developed in the course of the performance of the services referred to
above, considered in the light of our understanding of the applicable law,
nothing came to our attention that caused us to believe that the Registration
Statement (other than the financial statements and schedules and the other
financial and statistical data included therein, as to which we express no
belief), as of their dates, contained any untrue statement of a material fact or
omitted to state any material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not
misleading.
EXHIBIT E
FORM OF OFFICER'S CERTIFICATE
This Officer's Certificate ("Certificate") is being delivered
pursuant to Section 7(e) of that certain Common Stock Purchase Agreement dated
as of _________, ("Common Stock Purchase Agreement"), by and between
___________, a _______ corporation (the "Company"), and FUSION CAPITAL FUND II,
LLC (the "Buyer"). Terms used herein and not otherwise defined shall have the
meanings ascribed to them in the Common Stock Purchase Agreement.
The undersigned, ___________, ______________ of the Company, hereby
certifies as follows:
1. I am the _____________ of the Company and make the
statements contained in this Certificate;
2. The representations and warranties of the Company are true
and correct in all material respects (except to the extent that any of
such representations and warranties is already qualified as to
materiality in Section 3 of the Common Stock Purchase Agreement, in
which case, such representations and warranties shall be true and
correct without further qualification) as of the date when made and as
of the Commencement Date as though made at that time (except for
representations and warranties that speak as of a specific date);
3. The Company has performed, satisfied and complied in all
material respects with covenants, agreements and conditions required by
the Transaction Documents to be performed, satisfied or complied with
by the Company at or prior to the Commencement Date.
IN WITNESS WHEREOF, I have hereunder signed my name on this ___ day of
___________.
______________________________
Name:
Title:
The undersigned as Secretary of ________, a ________ corporation,
hereby certifies that ___________ is the duly elected, appointed, qualified and
acting ________ of _________ and that the signature appearing above is his
genuine signature.
_____________________________
Secretary
EXHIBIT F
FORM OF COMPANY RESOLUTIONS
WHEREAS, there has been presented to the Board of Directors of
________, (the "Corporation") a draft of a Common Stock Purchase Agreement (the
"Purchase Agreement") by and among the Corporation and Fusion Capital Fund II,
LLC ("Fusion"), providing for the purchase by Fusion of up to _____________
Dollars ($_________) of the Corporation's common stock, par value $___ (the
"Common Stock"); and
WHEREAS, after careful consideration of the Purchase Agreement, the
documents incident thereto and other factors deemed relevant by the Board of
Directors, the Board of Directors has determined that it is advisable and in the
best interests of the Corporation to engage in to transactions contemplated by
the Purchase Agreement.
Transaction Documents
RESOLVED, that the transactions described in the Purchase Agreement are
hereby approved and ____________________________________________ (the
"Authorized Officers") are severally authorized to execute and deliver the
Purchase Agreement, and any other agreements or documents contemplated thereby
(including, without limitation, a registration rights agreement (the
"Registration Rights Agreement") providing for the sale of the shares of the
Company's Common Stock issuable in respect of the Purchase Agreement) on behalf
of the Corporation, with such amendments, changes, additions and deletions as
the Authorized Officers may deem to be appropriate and approve on behalf of, the
Corporation, such approval to be conclusively evidenced by the signature of an
Authorized Officer thereon; and
FURTHER RESOLVED, that the terms and provisions of the Registration
Rights Agreement by and among the Corporation and Fusion are hereby approved and
the Authorized Officers are authorized to execute and deliver the Registration
Rights Agreement (pursuant to the terms of the Purchase Agreement), with such
amendments, changes, additions and deletions as the Authorized Officer may deem
appropriate and approve on behalf of, an Corporation, such approval to be
conclusively evidenced by the signature of an Authorized Officer thereon; and
FURTHER RESOLVED, that the terms and provisions of the Form of Transfer
Agent Instructions (the "Instructions") are hereby approved and the Authorized
Officers are authorized to execute and deliver the Instructions (pursuant to the
terms of the Purchase Agreement), with such amendments, changes, additions and
deletions as the Authorized Officers may deem appropriate and approve on behalf
of, the Corporation, such approval to be conclusively evidenced by the signature
of an Authorized Officer thereon; and
Execution of Purchase Agreement
FURTHER RESOLVED, that the Corporation be and it hereby is authorized
to execute the Purchase Agreement providing for the purchase of common stock of
the Corporation having an aggregate value of up to $___________; and
Issuance of Common Stock
FURTHER RESOLVED, that the Corporation is hereby authorized to issue
the Commitment Shares
(as defined in the Purchase Agreement) and that, upon issuance of the Commitment
Shares pursuant to the Purchase Agreement, the Commitment Shares will be duly
authorized, validly issued, fully paid and nonassessable with no personal
liability attaching to the ownership thereof; and
FURTHER RESOLVED, that the Corporation is hereby authorized to issue
shares of Common Stock upon the purchase of shares of Common Stock up to the
available amount under the Purchase Agreement (the "Purchase Shares") in
accordance with the terms of the Purchase Agreement and that, upon issuance of
the Purchase Shares pursuant to the Purchase Agreement, the Purchase Shares will
be duly authorized, validly issued, fully paid and nonassessable with no
personal liability attaching to the ownership thereof; and
FURTHER RESOLVED, that the Corporation shall initially reserve
_________ shares of Common Stock for issuance as Purchase Shares under the
Purchase Agreement.
Registration Statement
The management of the Corporation has prepared an initial draft of a
Registration Statement on Form ___ (the "Registration Statement") in order to
register the sale of the Purchase Shares and the Commitment Shares
(collectively, the "Shares"); and
The Board of Directors has determined to approve the Registration
Statement and to authorize the appropriate officers of the Corporation to take
all such actions as they may deem appropriate to effect the Offering; and
NOW, THEREFORE, BE IT RESOLVED, that the officers and directors of the
Corporation be, and each of them hereby is, authorized and directed, with the
assistance of counsel and accountants for the Corporation, to prepare, execute
and file with the Securities and Exchange Commission (the "Commission") the
Registration Statement, which Registration Statement shall be filed
substantially in the form presented to the Board of Directors, with such changes
therein as the Chief Executive Officer of the Corporation or any Vice President
of the Corporation shall deem desirable and in the best interest of the
Corporation and its shareholders (such officer's execution thereof including
such changes shall be deemed to evidence conclusively such determination); and
FURTHER RESOLVED, that the officers of the Corporation be, and each of
them hereby is, authorized and directed, with the assistance of counsel and
accountants for the Corporation, to prepare, execute and file with the
Commission all amendments, including post-effective amendments, and supplements
to the Registration Statement, and all certificates, exhibits, schedules,
documents and other instruments relating to the Registration Statement, as such
officers shall deem necessary or appropriate (such officer's execution and
filing thereof shall be deemed to evidence conclusively such determination); and
FURTHER RESOLVED, that the execution of the Registration Statement and
of any amendments and supplements thereto by the officers and directors of the
Corporation be, and the same hereby is, specifically authorized either
personally or by the Authorized Officers as such officer's or director's true
and lawful attorneys-in-fact and agents; and
FURTHER RESOLVED, that the Authorized Officers are hereby is designated
as "Agent for Service" of the Corporation in connection with the Registration
Statement and the filing thereof with the Commission, and the Authorized
Officers hereby are, authorized to receive communications and notices from the
Commission with respect to the Registration Statement; and
FURTHER RESOLVED, that the officers of the Corporation be, and each of
them hereby is, authorized and directed to pay all fees, costs and expenses that
may be incurred by the Corporation in connection with the Registration
Statement; and
FURTHER RESOLVED, that it is desirable and in the best interest of the
Corporation that the Shares be qualified or registered for sale in various
states; that the officers of the Corporation be, and each of them hereby is,
authorized to determine the states in which appropriate action shall be taken to
qualify or register for sale all or such part of the Shares as they may deem
advisable; that said officers be, and each of them hereby is, authorized to
perform on behalf of the Corporation any and all such acts as they may deem
necessary or advisable in order to comply with the applicable laws of any such
states, and in connection therewith to execute and file all requisite papers and
documents, including, but not limited to, applications, reports, surety bonds,
irrevocable consents, appointments of attorneys for service of process and
resolutions; and the execution by such officers of any such paper or document or
the doing by them of any act in connection with the foregoing matters shall
conclusively establish their authority therefor from the Corporation and the
approval and ratification by the Corporation of the papers and documents so
executed and the actions so taken; and
FURTHER RESOLVED, that if, in any state where the securities to be
registered or qualified for sale to the public, or where the Corporation is to
be registered in connection with the public offering of the Securities, a
prescribed form of resolution or resolutions is required to be adopted by the
Board of Directors, each such resolution shall be deemed to have been and hereby
is adopted, and the Secretary is hereby authorized to certify the adoption of
all such resolutions as though such resolutions were now presented to and
adopted by the Board of Directors; and
FURTHER RESOLVED, that the officers of the Corporation with the
assistance of counsel be, and each of them hereby is, authorized and directed to
take all necessary steps and do all other things necessary and appropriate to
effect the listing of the Shares on the __________.
Approval of Actions
RESOLVED, that, without limiting the foregoing, the Authorized Officers
are, and each of them hereby is, authorized and directed to proceed on behalf of
the Corporation and to take all such steps as deemed necessary or appropriate,
with the advice and assistance of counsel, to cause the Corporation to
consummate the agreements referred to herein and to perform its obligations
under such agreements; and
RESOLVED, that the Authorized Officers be, and each of them hereby is,
authorized, empowered and directed on behalf of and in the name of the
Corporation, to take or cause to be taken all such further actions and to
execute and deliver or cause to be executed and delivered all such further
agreements, amendments, documents, certificates, reports, schedules,
applications, notices, letters and undertakings and to incur and pay all such
fees and expenses as in their judgment shall be necessary, proper or desirable
to carry into effect the purpose and intent of any and all of the foregoing
resolutions, and that all actions heretofore taken by any officer or director of
the Corporation in connection with the transactions contemplated by the
agreements described herein are hereby approved, ratified and confirmed in all
respects.
EXHIBIT G
FORM OF TRANSFER AGENT INSTRUCTIONS
[Commencement Date]
[TRANSFER AGENT]
[Address]
Attn: __________________
Ladies and Gentlemen:
Reference is made to that certain Common Stock Purchase Agreement (the
"Common Stock Purchase Agreement"), dated as of ____________, by and between
_______, a _________ corporation (the "Company"), and FUSION CAPITAL FUND II,
LLC (together with its assigns, the "Buyer"), pursuant to which the Company may
sell to the Buyer up to ___________ Dollars ($_______) of the Company's common
stock, par value $___ per share (the "Common Stock"). The shares of Common Stock
to be purchased thereunder are referred to herein as, the "Purchase Shares."
This letter shall serve as our irrevocable authorization and direction to you
(provided that you are the transfer agent of the Company at such time) to issue
the Purchase Shares to the Buyer from time to time upon surrender to you of a
properly completed and duly executed Purchase Notice, in the form attached
hereto as Exhibit I, and a Company Confirmation of Purchase Notice, in the form
attached hereto as Exhibit II.
Specifically, upon receipt by the Company of a copy of a Purchase
Notice, the Company shall as soon as practicable, but in no event later than one
(1) Trading Day (as defined below) after receipt of such Purchase Notice, send,
via facsimile, a Company Confirmation of Purchase Notice to the Buyer and to
you, which confirmation shall constitute an irrevocable instruction to you to
process such Purchase Notice in accordance with the terms of these instructions
and the Company Confirmation of Purchase Notice. Upon your receipt of a copy of
the executed Purchase Notice and a copy of the applicable Company Confirmation
of Purchase Notice, you shall use your best efforts to, within one (1) Trading
Day following the date of receipt of the Company Confirmation of Purchase
Notice, (A) issue and surrender to a common carrier for overnight delivery to
the address as specified in the Purchase Notice, a certificate, registered in
the name of the Buyer or its designee, for the number of shares of Common Stock
to which the Buyer shall be entitled as set forth in the Company Confirmation of
Purchase Notice or (B) provided you are participating in The Depository Trust
Company ("DTC") Fast Automated Securities Transfer Program, upon the request of
the Buyer, credit such aggregate number of shares of Common Stock to which the
Buyer shall be entitled to the Buyer's or its designee's balance account with
DTC through its Deposit Withdrawal At Custodian ("DWAC") system provided the
Buyer causes its bank or broker to initiate the DWAC transaction. ("Trading Day"
shall mean any day on which the Nasdaq Market is open for customary trading.)
The Company hereby confirms to you and the Buyer that certificates
representing the Purchase Shares shall not bear any legend restricting transfer
of the Purchase Shares thereby and should not be subject to any stop-transfer
restrictions and shall otherwise be freely transferable on the books and records
of the Company provided that the Company counsel delivers the Notice of
Effectiveness set forth in Exhibit III attached hereto, and that if the Purchase
Shares are not registered for sale under the Securities Act of 1933, as amended,
then the certificates for the Purchase Shares shall bear the following legend:
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED
FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL, IN A FORM REASONABLY
ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID
ACT OR APPLICABLE STATE SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE
144 UNDER SAID ACT."
The Company hereby confirms to you and the Buyer that no instructions
other than as contemplated herein will be given to you by the Company with
respect to the Purchase Shares.
Please be advised that the Buyer is relying upon this letter as an
inducement to purchase shares of Common Stock under the Common Stock Purchase
Agreement and, accordingly, the Buyer is a third party beneficiary to these
instructions.
Should you have any questions concerning this matter, please contact me
at (___) ___-____.
Very truly yours,
___________________________
By:________________________
Name: __________________
Its: __________________
ACKNOWLEDGED AND AGREED:
[TRANSFER AGENT]
By:__________________________________
Name:________________________________
Title________________________________
Date:________________________________
CC: FUSION CAPITAL FUND II, LLC
EXHIBIT I
TO TRANSFER AGENT INSTRUCTIONS
FORM OF PURCHASE NOTICE
See attached.
[Attach Exhibit A to Common Stock Purchase Agreement.]
EXHIBIT II
TO TRANSFER AGENT INSTRUCTIONS
FORM OF COMPANY CONFIRMATION OF PURCHASE NOTICE
See attached.
[Attach Exhibit B to Common Stock Purchase Agreement.]
EXHIBIT III
TO TRANSFER AGENT INSTRUCTIONS
FORM OF NOTICE OF EFFECTIVENESS
OF REGISTRATION STATEMENT
[Date]
[TRANSFER AGENT]
[Address]
Attn: __________________
Ladies and Gentlemen:
We are counsel to _______, a ___________ corporation (the "Company"),
and have represented the Company in connection with that certain Common Stock
Purchase Agreement (the "Common Stock Purchase Agreement") entered into as of
_________, by and between the Company and FUSION CAPITAL FUND II, LLC (the
"Buyer") pursuant to which (i) the Company may sell to the Buyer up to
___________ Dollars ($___________) of the Company's common stock, par value
$____ per share (the "Common Stock" and the shares of Common Stock to be
purchased thereunder are referred to herein as, the "Purchase Shares"), and (ii)
the Company has agreed to issue to the Buyer _______ shares of Common Stock (the
"Commitment Shares"). Pursuant to the Common Stock Purchase Agreement, the
Company also has entered into a Registration Rights Agreement with the Buyer
(the "Registration Rights Agreement") pursuant to which the Company agreed,
among other things, to register the Purchase Shares and the Commitment Shares
under the Securities Act of 1933, as amended (the "1933 Act"). In connection
with the Company's obligations under the Common Stock Purchase Agreement and the
Registration Rights Agreement, on _____________, the Company filed a
Registration Statement (File No. 333-_____________) (the "Registration
Statement") with the Securities and Exchange Commission (the "SEC") relating to
the sale of the Purchase Shares and the Commitment Shares.
In connection with the foregoing, we advise you that a member of the
SEC's staff has advised us by telephone that the SEC has entered an order
declaring the Registration Statement effective under the 1933 Act at [ENTER TIME
OF EFFECTIVENESS] on [ENTER DATE OF EFFECTIVENESS] and we have no knowledge,
after telephonic inquiry of a member of the SEC's staff, that any stop order
suspending its effectiveness has been issued or that any proceedings for that
purpose are pending before, or threatened by, the SEC and the Purchase Shares
and the Commitment Shares are available for sale under the 1933 Act pursuant to
the Registration Statement.
The Buyer has confirmed it shall comply with all securities laws and
regulations applicable to it including applicable prospectus delivery
requirements upon sale of the Commitment Shares or the Purchase Shares.
Very truly yours,
[Company Counsel]
By:____________________
CC: FUSION CAPITAL FUND II, LLC
EXHIBIT H
FORM OF SECRETARY'S CERTIFICATE
This Secretary's Certificate ("Certificate") is being delivered
pursuant to Section 7(k) of that certain Common Stock Purchase Agreement dated
as of __________, ("Common Stock Purchase Agreement"), by and between _______, a
________ corporation (the "Company") and FUSION CAPITAL FUND II, LLC (the
"Buyer"), pursuant to which the Company may sell to the Buyer up to __________
Dollars ($___________) of the Company's Common Stock, par value $_____ per share
(the "Common Stock"). Terms used herein and not otherwise defined shall have the
meanings ascribed to them in the Common Stock Purchase Agreement.
The undersigned, ____________, Secretary of the Company, hereby certifies as
follows:
1. I am the Secretary of the Company and make the statements
contained in this Secretary's Certificate.
2. Attached hereto as Exhibit A and Exhibit B are true,
correct and complete copies of the Company's bylaws ("Bylaws") and
Certificate of Incorporation ("Articles"), in each case, as amended
through the date hereof, and no action has been taken by the Company,
its directors, officers or shareholders, in contemplation of the filing
of any further amendment relating to or affecting the Bylaws or
Articles.
3. Attached hereto as Exhibit C are true, correct and complete
copies of the resolutions duly adopted by the Board of Directors of the
Company on _____________, at which a quorum was present and acting
throughout. Such resolutions have not been amended, modified or
rescinded and remain in full force and effect and such resolutions are
the only resolutions adopted by the Company's Board of Directors, or
any committee thereof, or the shareholders of the Company relating to
or affecting (i) the entering into and performance of the Common Stock
Purchase Agreement, or the issuance, offering and sale of the Purchase
Shares and the Commitment Shares and (ii) and the performance of the
Company of its obligation under the Transaction Documents as
contemplated therein.
4. As of the date hereof, the authorized, issued and reserved
capital stock of the Company is as set forth on Exhibit D hereto.
IN WITNESS WHEREOF, I have hereunder signed my name on this
___ day of ____________.
____________________________
Secretary
The undersigned as ___________ of __________, a ________ corporation,
hereby certifies that ____________ is the duly elected, appointed, qualified and
acting Secretary of _________, and that the signature appearing above is his
genuine signature.
______________________________
Exhibit 10.56
Neither the warrant represented by this certificate (the "Warrant") nor the
shares issuable upon exercise thereof (the "Warrant Shares") have been
registered under the Securities Act of 1933, as amended (the "Act"), or
registered or qualified under applicable state securities laws. Atlantic
Technology Ventures, Inc. (the "Company") is not required to give effect to any
transfer of the Warrant or the Warrant Shares unless (1) there is an effective
registration statement under the Act with respect to the Warrant or the Warrant
Shares, as applicable, and the Warrant or the Warrant Shares, as applicable, are
registered or qualified under applicable state securities laws, or (2) the
holder of the Warrant provides to Atlantic an opinion of counsel reasonably
acceptable to Atlantic to the effect that such transfer may be made without
registration under the Act and applicable state securities laws.
ATLANTIC TECHNOLOGY VENTURES, INC.
WARRANT CERTIFICATE
This warrant certificate certifies that DIAN GRIESEL, or her permitted
assigns (the "Holder"), is the owner of a warrant (the "Warrant") entitling her
at any time prior to the Expiration Date to purchase from Atlantic Technology
Ventures, Inc., a Delaware corporation ("Atlantic"), for a purchase price of
$0.875 per share (the "Exercise Price"), 120,000 shares of common stock, par
value $0.001 per share, of Atlantic (the "Common Stock"; those shares, "Warrant
Shares"), the number of Warrant Shares and the Exercise Price being subject to
adjustment as provided herein.
1. Exercise. The Warrant is exercisable, at the option of the Holder,
in whole or in part at any time after issuance and prior to the Expiration Date
upon surrender of this warrant certificate to Atlantic, together with a duly
completed Notice of Exercise in the form attached hereto as Annex A and payment
to Atlantic, simultaneous with delivery of the Notice of Exercise, of an amount
equal to the Exercise Price.
2. Expiration Date. "Expiration Date" means 5:00 p.m. New York time on
March 8, 2006.
3. Vesting. The number of shares of Common Stock for which the Warrant
is exercisable is 5,000 as of the date of this warrant certificate. That number
will increase by 5,000 on the eighth day of each of the following 23 months, on
condition that Dian Griesel continues serving as a consultant to Atlantic, and
that number will cease increasing once Dian Griesel ceases serving as a
consultant to Atlantic.
4. Partial Exercise. The Warrant may be exercised in part by surrender
of this Warrant Certificate in the manner provided in Section 1, except that the
amount payable by the Holder on such partial exercise is the amount obtained by
multiplying the number of Warrant Shares designated by the Holder in the Notice
of Exercise by the Exercise Price then in effect. On any such partial exercise
Atlantic at its expense must forthwith issue and deliver to or upon the order of
the Holder a warrant certificate in the name of the Holder or as the Holder
(upon payment by the Holder of any applicable transfer taxes) requests
containing terms substantially identical to those contained in this Warrant
Certificate evidencing a warrant for a number of Warrant Shares equal to the
number of Warrant Shares remaining unpurchased.
5. Registration and Transfer on Company Books. (a) Prior to due
presentment for registration of transfer of this warrant certificate or the
Warrant Shares, Atlantic may deem and treat the Holder as the absolute owner
thereof, regardless of any notice to the contrary.
(b) Atlantic shall register upon its books any transfer of this
warrant certificate upon its surrender to Atlantic with a written instrument of
transfer duly executed by the Holder or by a duly authorized attorney. Upon
registration of transfer, Atlantic shall issue a new Warrant Certificate to the
transferee and shall cancel the surrendered Warrant Certificate.
(c) Neither the Warrant nor the Warrant Shares have been registered
under the Securities Act of 1933, as amended (the "Act"), or registered or
qualified under applicable state securities laws. Atlantic is not required to
give effect to any transfer of the Warrant or the Warrant Shares unless (1)
there is an effective registration statement under the Act with respect to the
Warrant or the Warrant Shares, as applicable, and the Warrant or the Warrant
Shares, as applicable, are registered or qualified under applicable state
securities laws, or (2) the Holder provides to Atlantic an opinion of counsel
reasonably acceptable to Atlantic to the effect that such transfer may be made
without registration under the Act and applicable state securities laws.
6. Limited Transferability. The Holder may not without the prior
written consent of Atlantic transfer the Warrant or any Warrant Shares, which
consent may not be unreasonably withheld.
7. Reservation of Shares. Atlantic shall at all times reserve and keep
available out of its authorized capital stock, solely for the purpose of issue
upon exercise of the Warrant, the number of shares of capital stock then
issuable upon the exercise of the Warrant. Atlantic shall upon issue cause all
Warrant Shares to be duly and validly issued and fully paid and non-assessable
and free from all taxes, liens and charges with respect to the issue thereof,
and shall cause the Warrant Shares to be listed on each national securities
exchange, if any, on which the other shares of Common Stock are then listed.
8. Loss or Mutilation. Atlantic shall execute and deliver a new Warrant
Certificate in lieu of one that has been lost, stolen, destroyed or mutilated
upon receipt by Atlantic of reasonable evidence of ownership and either
indemnity reasonably satisfactory to Atlantic (in the case of loss, theft or
destruction) or surrender and cancellation of a mutilated Warrant Certificate.
9. Adjustment of Purchase Price and Number of Warrant Shares. The
number of Warrant Shares and the Purchase Price are subject to adjustment as
follows:
(1) If at any time after the date hereof Atlantic (A) declares a dividend or
makes a distribution on its outstanding shares of Common Stock payable in
shares of its capital stock, (B) subdivides its outstanding shares of
Common Stock through stock split or otherwise, (C) combines its
outstanding shares of Common Stock into a smaller number of shares of
Common Stock, or issues by reclassification of its Common Stock (including
any reclassification in connection with a consolidation or merger in which
Atlantic is the continuing corporation) other securities of Atlantic, the
number or nature, or both, of the Warrant Shares on the record date
thereof (in the case of a dividend) or at
2
the effective time thereof (in the case of a subdivision, combination or
reclassification) will be adjusted so as to entitle the Holder to receive
after such time the number and nature of Warrant Shares or other
securities of Atlantic which the Holder would have been entitled to
receive by virtue of any of the events described above, had the Warrant
been exercised immediately prior to such time.
(2) If Atlantic distributes to all holders of shares of Common Stock, or all
holders of Common Stock otherwise become entitled to receive shares of
capital stock of Atlantic (other than dividends or distributions on its
Common Stock referred to in Section 9(a)(1)), evidences of its
indebtedness or rights, options, warrants or convertible securities
providing the right to subscribe for or purchase any shares of Atlantic's
capital stock or evidences of its indebtedness (other than any rights,
options, warrants or convertible securities referred to in Section
9(a)(2)), then in each case the number of Warrant Shares shall thereafter
be determined by multiplying the number of Warrant Shares prior thereto by
a fraction, the numerator of which is the Current Market Price on the
record date mentioned below in this Section 9(a)(2), and the denominator
of which is the Current Market Price on such record date minus the then
fair value (as determined by the Board of Directors of Atlantic, in good
faith, whose determination will be final, binding and conclusive on
Atlantic and the Holder) of the shares of Atlantic's capital stock other
than Common Stock, evidences of indebtedness, or of such rights, options,
warrants or convertible securities, distributed with respect to each share
of Common Stock. Such adjustment must be made whenever any such
distribution is made, and is effective retroactively as of the record date
for the determination of stockholders entitled to receive such
distribution.
(3) In the event of any capital reorganization or any reclassification of the
capital stock of Atlantic or in case of the consolidation or merger of
Atlantic with another corporation (other than a consolidation or merger in
which the outstanding shares of Common Stock are not converted into or
exchanged for other rights or interests and other than a reclassification
to which Section 9(a)(1)(D) applies), or in the case of any sale, transfer
or other disposition to another corporation of all or substantially all
the properties and assets of Atlantic, the Holder will thereafter be
entitled to purchase (and it must be a condition to the consummation of
such reorganization, reclassification, consolidation, merger, sale,
transfer or other disposition that the Holder thereafter be entitled to
purchase) the number and nature of shares of stock and other securities
and property (including cash) which the Holder would have been entitled to
receive had the Warrant been exercised immediately prior to the effective
date of such reorganization, reclassification, consolidation, merger,
sale, transfer or other disposition; and in any such case appropriate
adjustments must be made in the application of the provisions of this
Section 9 with respect to rights and interest thereafter of the Holder to
the end that the provisions of this Section 9 thereafter be applicable, as
near as reasonably may be, in relation to any shares or other property
thereafter purchasable upon the exercise of the Warrant. The provisions of
this Section 9(a)(3) are similarly apply to successive reorganizations,
reclassifications, consolidations, mergers, sales, transfers or other
dispositions.
(4) Whenever the number of Warrant Shares purchasable upon the exercise of the
Warrant is adjusted, as provided in this Section 9(a), the Exercise Price
must be adjusted by
3
multiplying the Exercise Price immediately prior to such adjustment by a
fraction, the numerator of which is the number of Warrant Shares
immediately prior to such adjustment, and the denominator of which is the
number of Warrant Shares immediately thereafter.
(b) In the event Atlantic declares a dividend, or makes a
distribution to the holders of shares of Common Stock generally, whether in
cash, property or assets of any kind, or any dividend payable in stock or
securities of any other issuer owned by Atlantic (excluding cash dividends
payable out of current or retained earnings declared from time to time by
Atlantic's Board of Directors or any dividend or distribution referred to in
Section 9(a)(1) or Section 9(a)(2)), the Exercise Price will be reduced, without
any further action by the parties hereto, by the Per Share Value (as hereinafter
defined) of the dividend. For purposes of this Section 9(b), the "Per Share
Value" of a cash dividend or other distribution shall be the dollar amount of
the distribution on each share of Common Stock and the "Per Share Value" of any
dividend or distribution other than cash is equal to the fair market value of
such non-cash distribution on each share of Common Stock as determined in good
faith by the Board of Directors of Atlantic, whose determination will be final,
binding and conclusive on Atlantic and the Holder.
(c) No adjustment in the number of Warrant Shares, or in the
Exercise Price, is required unless such adjustment would require an increase or
decrease of at least 3% in the number of Warrant Shares or in the Exercise
Price, except that any adjustments which by reason of this Section 9(c) are not
required to be made will be carried forward and taken into account in any
subsequent adjustment. All final results of adjustments to the number of Warrant
Shares and the Exercise Price must be rounded to the nearest one hundredth of a
share or the nearest cent, as the case may be. Anything in this Section 9 to the
contrary notwithstanding, Atlantic is entitled, but not required, to make such
changes in the number of Warrant Shares or in the Exercise Price, in addition to
those required by this Section 9, as it in its discretion determines to be
advisable in order to ensure that any dividend or distribution in shares of
Common Stock, subdivision, reclassification or combination of shares of Common
Stock, issuance of rights, warrants or options to purchase Common Stock, or
distribution of shares of stock other than Common Stock, evidences of
indebtedness or assets (other than distributions of cash out of retained
earnings) or convertible or exchangeable securities hereafter made by Atlantic
to the holders of its Common Stock does not result in any tax to the holders of
Common Stock or securities convertible into Common Stock.
(d) Whenever the number of Warrant Shares or the Exercise Price is
adjusted, as herein provided, Atlantic shall mail to the Holder, at the address
of the Holder shown on the books of Atlantic, a notice of such adjustment or
adjustments, prepared and signed by the Chief Financial Officer or Secretary of
Atlantic, setting forth the number of Warrant Shares and the Exercise Price
after such adjustment, a brief statement of the facts requiring such adjustment
and the computation by which such adjustment was made. In the absence of
manifest error, this computation will be final, binding and conclusive on
Atlantic and the Holder.
(e) In the event that at any time prior to the Expiration Date and
prior to exercise of the Warrant:
4
(1) Atlantic declares any distribution (other than a cash dividend or a
dividend payable in securities of Atlantic with respect to the Common
Stock); or
(2) Atlantic offers for subscription to the holders of the Common Stock any
additional shares of stock of any class or any other securities
convertible into Common Stock or any rights to subscribe thereto; or
(3) Atlantic declares any stock split, stock dividend, subdivision,
combination, or similar distribution with respect to the Common Stock,
regardless of the effect of any such event on the outstanding number of
shares of Common Stock; or
(4) Atlantic declares a dividend, other than a dividend payable in shares of
Atlantic's own Common Stock; or
(5) there is any capital change in Atlantic as set forth in Section 9(a)(3);
or
(6) there is a voluntary or involuntary dissolution, liquidation or winding up
of Atlantic (other than in connection with a consolidation, merger or sale
of all or substantially all of its property, assets and business as an
entity);
(each such event hereinafter being referred to as a "Notification Event"),
Atlantic shall cause to be mailed to the Holder, not less than 20 days prior to
the record date, if any, in connection with such Notification Event (or as soon
as practicable, if there is no record date, or if 20 days prior notice is
impracticable) written notice specifying the nature of such event and the
effective date of, or the date on which the books of Atlantic will close or a
record will be taken with respect to, such event. Such notice must also set
forth facts indicating the effect of such action (to the extent this effect is
known at the date of such notice) on the Exercise Price and the kind and amount
of the shares of stock or other securities or property deliverable upon exercise
of the Warrant.
(f) The form of Warrant Certificate need not be changed because of
any change in the number of Warrant Shares or the Exercise Price, and any
Warrant Certificate issued before or after such change may state the same number
of Warrant Shares and the same Exercise Price as stated in the Warrant
Certificates theretofore issued. Atlantic may, however, at any time, in its sole
discretion, make any change in the form of Warrant Certificate that it deems
appropriate and that does not affect the substance thereof, and any Warrant
Certificates thereafter issued or countersigned, whether in exchange or
substitution for an outstanding Warrant Certificate or otherwise, may be in the
form as so changed.
10. Voluntary Adjustment by Atlantic. Atlantic may, at its option, at
any time reduce the then current Exercise Price to any amount deemed appropriate
by the Board of Directors of Atlantic or extend the Expiration Date, or both.
11. Fractional Shares. Anything contained herein to the contrary
notwithstanding, Atlantic is not required to issue any fraction of a share of
Common Stock in connection with the exercise of the Warrant. Upon exercise of
the Warrant, Atlantic shall issue to the Holder the largest aggregate whole
number of shares of Common Stock called for thereby upon receipt of the
aggregate Exercise Price and shall pay a sum in cash equal to the remaining
fraction of a
5
share of Common Stock, multiplied by the Current Market Price (as determined
pursuant to Section 12) as of the last business day preceding the date on which
the Warrant is presented for exercise.
12. Determination of Current Market Price. (a) As used herein, "Current
Market Price" means, as of each date of determination, the following:
(1) if there is a public market for the Common Stock, the average of the daily
market price per share of Common Stock for 20 consecutive days that the
public market is open for business (each such day, a "Trading Day") before
the date of determination; and
(2) if there is no such public market, the Appraised Value Per Share.
(b) The daily market price for each Trading Day is as follows:
(1) the last sale price on that Trading Day on the principal stock exchange on
which the Common Stock is then listed or admitted to trading;
(2) if no sale takes place on that Trading Day on that exchange, the average
of the last reported closing bid and asked prices on that Trading Day as
officially quoted on that exchange;
(3) if the Common Stock is not then listed or admitted to trading on any stock
exchange, the average of the last reported closing bid and asked prices on
that Trading Day in the over-the-counter market, as furnished by the
NASD's Automatic Quotation System or the National Quotation Bureau, Inc.;
(4) if neither NASD's Automatic Quotation System nor the National Quotation
Bureau, Inc. is at the time engaged in the business of reporting such
prices, as furnished by any similar Person then engaged in that business;
or
(5) if there is no such Person, as furnished by any member of the NASD
selected by the Holder and Atlantic or, if they cannot agree upon such
selection, as selected by two such members of the NASD, one of which is
selected by the Holder and one of which is selected by Atlantic.
(c) As used in this warrant certificate, "Appraised Value Per Share"
means, as of each date of determination, the fair saleable value of the Common
Stock as of the last day of the most recent fiscal month ending prior to such
date divided by the number of Fully Diluted Outstanding shares of Common Stock.
The Appraised Value Per Share must be made by a U.S. investment banking firm of
nationally recognized standing selected jointly by the Holder and Atlantic. If
the Holder and Atlantic are unable to agree upon an investment banking firm,
then the Holder and Atlantic shall each choose one such investment banking firm
and the respective chosen firms must agree on another investment banking firm,
which must make the determination. Atlantic shall retain, at its sole cost, the
investment banking firm responsible for determining the Appraised Value Per
Share. The Appraised Value Per Share must (1) be determined on a consolidated
basis without giving effect to any discount for (A) minority interest or (B) any
lack of liquidity of the Common Stock or, if applicable, Atlantic not having any
class
6
of equity registered under the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and (2) must be based on the sale of Atlantic in an
arms'-length sale between a willing buyer and a willing seller with neither
acting under compulsion.
13. Tax. The issuance of any shares or other securities upon the
exercise of the Warrant, and the delivery of certificates or other instruments
representing such shares or other securities, will be without charge to the
Holder for any tax or other charge in respect of such issuance. Atlantic is not,
however, required to pay any tax which may be payable in respect of any transfer
involved in the issue and delivery of any certificate in a name other than that
of the Holder and Atlantic is not required to issue or deliver any such
certificate unless and until the person or persons requesting the issue thereof
have paid to Atlantic the amount of such tax or have established to the
satisfaction of Atlantic that such tax has been paid.
14. Legend. The Warrant Shares issued on exercise of the Warrants will
be subject to a stop transfer order and the certificate or certificates
representing the Warrant Shares must bear the following legend:
The securities represented by this certificate have not been registered
under the Securities Act of 1933, as amended (the "Act"), or registered
or qualified under applicable state securities laws. Atlantic
Technology Ventures, Inc. ("Atlantic") is not required to give effect
to any transfer of these securities unless (1) there is an effective
registration statement under the Act with respect to these securities
and these securities are registered or qualified under applicable state
securities laws or (2) Atlantic is provided with an opinion of counsel
reasonably acceptable to Atlantic to the effect that such transfer may
be made without registration under the Act and applicable state
securities laws pursuant to an applicable exemption from the
registration requirements of the Act and those laws.
15. No Rights as Stockholder. The Holder does not have solely on
account of that status any rights of a stockholder of Atlantic, either at law or
in equity, or to any notice of meetings of stockholders or of any other
proceedings of Atlantic, except as provided in this warrant certificate.
16. Notices. Every notice or other communication required or
contemplated by this Warrant must be in writing and sent by one of the following
methods: (1) personal delivery, in which case delivery is deemed to occur the
day of delivery; (2) transmission by telecopy with acknowledgement of receipt,
in which case delivery is deemed to occur the day of transmission; (3) certified
or registered mail, postage prepaid, return receipt requested, in which case
delivery is deemed to occur the day it is officially recorded as delivered to
the intended recipient; (4) for delivery from a U.S. address to a non-U.S.
address, or vice versa, delivery by recognized express delivery service such as
Federal Express or DHL Worldwide Express, in which case delivery will be deemed
to occur three days after sending; or (5) for delivery from one U.S. address to
another, next-day delivery by recognized overnight delivery service such as
Federal Express, in which case delivery is deemed to occur the day after
sending. In each case, a notice or other communication sent to a party must be
directed to the coordinates for that party set forth below, or to other
coordinates designated by that party by written notice:
7
if to the Holder, at her last known address appearing on the books of
Atlantic maintained for such purpose; and
if to Atlantic at:
Atlantic Technology Ventures, Inc.
350 Fifth Avenue
Suite 5507
New York, NY 10118
Attention: Frederic P. Zotos, President
17. Governing Law. This warrant certificate is governed by the laws of
the State of New York without regard to principles of conflict of laws.
Atlantic is executing this warrant certificate as of March 8, 2001.
ATLANTIC TECHNOLOGY VENTURES, INC.
By:
-------------------------------------
Frederic P. Zotos
President
8
Annex A
NOTICE OF EXERCISE
The undersigned hereby irrevocably elects to exercise the Warrant owned
by the undersigned pursuant to the accompanying Warrant Certificate for, and to
purchase thereunder, ______ shares of common stock, par value $0.001 per share,
of Atlantic Technology Ventures, Inc., and herewith makes payment of the
Exercise Price (as defined in the Warrant Certificate) of those shares in full
as provided in the Warrant Certificate.
____________________________
Print Name
____________________________
Signature
Address of Holder:
____________________________
____________________________
____________________________
____________________________